Transforming growth factor-beta responsive polypeptides and use methods thereof
Patent Information
- Application Number
- JP2024134780
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-10-30
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2036-10-28
AI Technical Summary
Current treatments for neutralizing TGF-β in the tumor microenvironment, such as antibodies and chemical inhibitors, are costly and often associated with toxicity issues, and simply neutralizing TGF-β signals may not be sufficient to stimulate an effective immune response.
Development of polypeptides that intracellularly neutralize TGF-β and induce T cell activation by incorporating a signal peptide, antigen-binding domain, peptide spacer, transmembrane domain, and endodomain, specifically designed to bind TGF-β and convert its immunosuppressive signal to an activating stimulus.
The polypeptides effectively neutralize TGF-β while stimulating immune responses, leading to increased production of immunostimulatory cytokines and T cell proliferation, providing a more effective and cost-efficient therapeutic strategy.
Smart Images

Figure 00000094_0000 
Figure 00000094_0001 
Figure 00000094_0002
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 248,685, filed October 30, 2015. The entire contents of the above-referenced disclosures are specifically incorporated herein by reference without disclaimer.
[0002] This invention was made with Government support under Grant Nos. CA183528 and OD012133 awarded by the National Institutes of Health. The Government has certain rights in this invention.
[0003] 1. Field of the Invention The present invention relates generally to the fields of biotechnology and medicine. In particular, the present invention relates to polypeptides and cells comprising the polypeptides that are useful for stimulating an immune response in the presence of TGF-β. [Background technology]
[0004] 2. Background TGF-β is a pleiotropic cytokine found at high levels in a variety of pathological conditions, including solid tumors, fibrosis, and dysregulated wounds. Treatment strategies for solid tumors have been targeted at neutralizing TGF-β in the tumor microenvironment. Although a variety of anti-TGF-β antibodies exist, antibodies as therapeutic agents have several drawbacks. For example, antibodies can be large compared to other antigen-binding molecules and are multi-chain proteins encoded by multiple genes. Both of these aspects lead to high production costs. Additionally, chemicals that inhibit TGF-β have been identified, but they often have toxicity issues due to metabolic by-products in the liver.
[0005] Strategies using adoptive T cell therapy with TGF-β-insensitive T cells expressing dominant-negative TGF-β receptors are being explored. However, neutralization of TGF-β signaling alone may not be sufficient, and reversing TGF-β signaling from immunosuppression to immunostimulation may provide a more promising therapeutic strategy.
[0006] Thus, there is a need in the art for more effective therapies that neutralize the effects of TGF-β, while also providing the benefit of cost-effective production. Summary of the Invention
[0007] The polypeptides described herein fulfill a need in the art by providing a polypeptide that, when expressed intracellularly, not only neutralizes TGF-β, but can also specifically induce T cell activation in the presence of TGF-β. T cell activation prompts immune cells to produce immunostimulatory cytokines and proliferate, thereby transforming TGF-β from an immunosuppressive signal into an activating stimulus. Thus, aspects of the present disclosure relate to a polypeptide comprising a signal peptide, an antigen-binding domain having a heavy chain variable (VH) region and a light chain variable (VL) region, a peptide spacer, a transmembrane domain, and an endodomain, wherein the antigen-binding domain specifically binds to TGF-β.
[0008] In some aspects, the disclosure relates to a polypeptide comprising a signal peptide, an antigen-binding domain having a heavy chain variable (VH) region and a light chain variable (VL) region, a peptide spacer, a transmembrane domain, and an endodomain, wherein the VH region comprises SEQ ID NO:5 (HCDR1), SEQ ID NO:6 (HCDR2), and SEQ ID NO:7 (HCDR3), and the VL region comprises SEQ ID NO:8 (LCDR1), SEQ ID NO:9 (LCDR2), and SEQ ID NO:10 (LCDR3). In some embodiments, the VH comprises SEQ ID NO:1 and the VL comprises SEQ ID NO:2.
[0009] In some aspects, the disclosure relates to a polypeptide comprising a signal peptide, an antigen-binding domain having a heavy chain variable (VH) region and a light chain variable (VL) region, a peptide spacer, a transmembrane domain, and an endodomain, wherein the VH region comprises SEQ ID NO:11 (HCDR1), SEQ ID NO:12 (HCDR2), and SEQ ID NO:13 (HCDR3), and the VL region comprises SEQ ID NO:14 (LCDR1), SEQ ID NO:15 (LCDR2), and SEQ ID NO:16 (LCDR3). In some embodiments, the VH comprises SEQ ID NO:3 and the VL comprises SEQ ID NO:4.
[0010] In some aspects, the disclosure relates to a polypeptide comprising a signal peptide, an antigen-binding domain having a heavy chain variable (VH) region and a light chain variable (VL) region, a peptide spacer, a transmembrane domain, and an endodomain, wherein the VH region comprises SEQ ID NO:21 (HCDR1), SEQ ID NO:22 (HCDR2), and SEQ ID NO:23 (HCDR3), and the VL region comprises SEQ ID NO:24 (LCDR1), SEQ ID NO:25 (LCDR2), and SEQ ID NO:26 (LCDR3). In some embodiments, the VH comprises SEQ ID NO:19 and the VL comprises SEQ ID NO:20.
[0011] The polypeptides described above and herein are continuous, single-chain polypeptides.
[0012] A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) has a certain percentage of "sequence identity" or "homology" to another sequence (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, or any range obtainable therein), meaning that the percentage of bases (or amino acids) are the same when the two sequences are aligned and compared. This alignment and percent homology or sequence identity can be calculated using software programs known in the art (e.g., programs described in Ausubel et al. eds. (2007) Current Protocols in Molecular Biology).
[0013] The polypeptides of the present disclosure may have a region, domain, linker, spacer, etc. that has at least, at most, or exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity (or any range obtainable therein) to all or a portion of the amino acid sequences described herein. In certain embodiments, the polypeptides described throughout the present disclosure are isolated, meaning that they are not found in a cellular environment. The polypeptides may also be purified, meaning that they are generally purified if not completely separated from polypeptides having different amino acid sequences and / or chemical formulas.
[0014] In some embodiments, the VH and VL are separated by a peptide linker. It is contemplated that the peptide linker may separate any of the domains / regions described in the polypeptides of the present disclosure. In some embodiments, the peptide linker is a peptide composed of only glycine and serine residues (glycine-serine linker). In some embodiments, the peptide linker is at least, at most, or exactly 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 100, 125, 150, or 200 amino acids (or any range obtainable therein). In some embodiments, the peptide linker is known in the art or described herein.
[0015] In some embodiments, a polypeptide has the structure SX-PL-Y-PS-TE or SY-PL-X-PS-TE, where S is a signal peptide, X is a VH, PL is a peptide linker, Y is a VL, PS is a peptide spacer, T is a transmembrane domain, and E is an endodomain. In some embodiments, a polypeptide has the structure SXY-PS-TE or SYX-PS-TE, where S, X, Y, PS, T, and E are defined above. When peptides and polypeptides are referred to herein, sequences and structures are described and interpreted from N-terminus to C-terminus, as is standard practice in the art.
[0016] In some embodiments, the polypeptide further comprises a costimulatory region. In some embodiments, the costimulatory region is between the transmembrane domain and the endodomain. In some embodiments, the polypeptide comprises at least, at most, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 costimulatory regions (or any range derivable therein). In some embodiments, the costimulatory region is known in the art or described herein.
[0017] In some embodiments, the transmembrane domain comprises the transmembrane domain of CD28. In some embodiments, the transmembrane domain is all or a portion of a transmembrane domain known in the art or described herein.
[0018] In some embodiments, the endodomain comprises CD28 signaling domain or CD3 zeta signaling domain, or both. In some embodiments, the endodomain is all or part of the endodomain known in the art or described herein. In some embodiments, the endodomain is CD3 zeta signaling domain. In some embodiments, the endodomain comprises one or more parts, for example 2, 3, 4, 5, 6, 7, 8, 9, 10 parts, of the suitable endodomain described herein.
[0019] In some embodiments, the peptide spacer comprises a hinge region. In some embodiments, the hinge is a hinge region of an IgG molecule. In some embodiments, the hinge is a hinge region known in the art or described herein. In some embodiments, the peptide spacer comprises or further comprises a CH2CH3 region of an IgG molecule. In some embodiments, the peptide spacer comprises one or more of a hinge region, a CH1 region, a CH2 region, and a CH3 region. In some embodiments, the peptide spacer is derived from a hinge region, a CH1 region, a CH2 region, and / or a CH3 region, or other region, of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, or IgM from human, mouse, rat, dog, donkey, goat, or rabbit. In some embodiments, the peptide spacer comprises a hinge region and a CH2CH3 region of an IgG molecule. In some embodiments, the CH2CH3 region of the IgG molecule further comprises the mutations L235E / N297Q or L235D / N297Q to prevent Fc receptor binding. In some embodiments, the peptide spacer consists of the hinge region of the IgG molecule. In some embodiments, the peptide spacer is less than 30, less than 20, less than 15, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, or less than 4 amino acids. In some embodiments, the peptide spacer is 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 160, 170, 180, 190, 20 The amino acid sequence may be less than, more than, or exactly 0, 210, 220, 225, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 450, 500, 550, 600, or 700 amino acids (or any range derivable therein).In some embodiments, the peptide spacer comprises fewer than 50 amino acids. In some embodiments, the peptide spacer comprises more than 50 amino acids.
[0020] In some embodiments, the polypeptide further comprises a detection peptide. In some embodiments, the detection peptide is a peptide of SEQ ID NO:17, an HA tag (SEQ ID NO:94), or a cMyc tag (SEQ ID NO:95). In some embodiments, the detection peptide is adjacent to a linker. In some embodiments, the linker (e.g., a peptide linker described herein) is at the amino portion of the detection peptide. In some embodiments, the linker (e.g., a peptide linker described herein) is at the carboxy portion of the detection peptide. In some embodiments, the linker is at the amino and carboxy portions of the detection peptide. In some embodiments, the detection peptide is at the amino portion of the VH and VL regions. In some embodiments, the detection peptide is between the signal peptide and the antigen binding domain.
[0021] In some embodiments, the signal peptide comprises SEQ ID NO: 18. In some embodiments, the signal peptide is known in the art or described herein.
[0022] In some embodiments, the polypeptide further comprises a cancer molecule-specific antigen binding domain. For example, the polypeptide may be a bispecific chimeric antigen receptor (CAR), and the polypeptide comprises an antigen binding domain for TGF-β and an antigen binding domain for a cancer molecule or a cancer antigen. These antigen binding domains may be separated by a peptide spacer or linker. In some embodiments, the cancer molecule comprises Her2. In some embodiments, the cancer molecule comprises CD19 or CD20. In some embodiments, the cancer molecule or cancer antigen is known in the art or described herein.
[0023] In some embodiments, the antigen-binding domain specifically binds to soluble TGF-β. It has not previously been known that polypeptides similar to those of the present disclosure can bind to and signal in response to soluble antigens.
[0024] The polypeptides described herein are selected from the group consisting of at least or at most 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 , 60 pieces, 61 pieces, 62 pieces, 63 pieces, 64 pieces, 65 pieces, 66 pieces, 67 pieces, 68 pieces, 69 pieces, 70 pieces, 71 pieces, 72 pieces, 73 pieces, 74 pieces, 75 pieces, 76 pieces, 77 pieces, 78 pieces, 79 pieces, 80 pieces, 81 pieces, 82 pieces, 83 pieces, 84 pieces, 85 pieces, 86 pieces, 87 pieces, 88 pieces, 89 pieces, 9 0 pieces, 91 pieces, 92 pieces, 93 pieces, 94 pieces, 95 pieces, 96 pieces, 97 pieces, 98 pieces, 99 pieces, 100 pieces, 101 pieces, 102 pieces, 103 pieces, 10 4 pieces, 105 pieces, 106 pieces, 107 pieces, 108 pieces, 109 pieces, 110 pieces, 111 pieces, 112 pieces, 113 pieces, 114 pieces, 115 pieces, 116 pieces, 117 pieces, 118 pieces, 119 pieces, 120 pieces, 121 pieces, 122 pieces, 123 pieces, 124 pieces, 125 pieces, 126 pieces, 127 pieces, 128 pieces pieces, 129 pieces, 130 pieces, 131 pieces, 132 pieces, 133 pieces, 134 pieces, 135 pieces, 136 pieces, 137 pieces, 138 pieces, 139 pieces, 140 pieces , 141 pieces, 142 pieces, 143 pieces, 144 pieces, 145 pieces, 146 pieces, 147 pieces, 148 pieces, 149 pieces, 150 pieces, 151 pieces, 152 pieces, 153 pieces, 154 pieces, 155 pieces, 156 pieces, 157 pieces, 158 pieces, 159 pieces, 160 pieces, 161 pieces, 162 pieces, 163 pieces, 164 pieces, 1 65 pieces, 166 pieces, 167 pieces, 168 pieces, 169 pieces, 170 pieces, 171 pieces, 172 pieces, 173 pieces, 174 pieces, 175 pieces, 176 pieces, 17 7 pieces, 178 pieces, 179 pieces, 180 pieces, 181 pieces, 182 pieces, 183 pieces, 184 pieces, 185 pieces, 186 pieces, 187 pieces, 188 pieces, 189 pieces, 190 pieces, 191 pieces, 192 pieces, 193 pieces, 194 pieces, 195 pieces, 196 pieces, 197 pieces, 198 pieces, 199 pieces, 200 pieces, 201 pieces , 202 pieces, 203 pieces, 204 pieces, 205 pieces, 206 pieces, 207 pieces, 208 pieces, 209 pieces, 210 pieces, 211 pieces, 212 pieces, 213 pieces,214 pieces, 215 pieces, 216 pieces, 217 pieces, 218 pieces, 219 pieces, 220 pieces, 221 pieces, 222 pieces, 223 pieces, 224 pieces, 225 pieces, 226 pieces, 227 pieces, 228 pieces, 229 pieces, 23 0 pieces, 231 pieces, 232 pieces, 233 pieces, 234 pieces, 235 pieces, 236 pieces, 237 pieces, 238 pieces, 239 pieces, 240 pieces, 241 pieces, 242 pieces, 243 pieces, 244 pieces, 245 pieces, 246 pieces, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 247, 248, 249, 250, 300, 400, 500, 550, 1000 or more consecutive amino acids, or within any range obtainable therein 24 pieces, 25 pieces, 26 pieces, 27 pieces, 28 pieces, 29 pieces, 30 pieces, 31 pieces, 32 pieces, 33 pieces, 34 pieces, 35 pieces, 36 pieces, 37 pieces, 38 pieces, 39 pieces, 40 pieces, 41 pieces, 42 pieces, 43 pieces, 44 pieces , 45 pieces, 46 pieces, 47 pieces, 48 pieces, 49 pieces, 50 pieces, 51 pieces, 52 pieces, 53 pieces, 54 pieces, 55 pieces, 56 pieces, 57 pieces, 58 pieces, 59 pieces, 60 pieces, 61 pieces, 62 pieces, 63 pieces, 64 pieces, 65 , 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more variant amino acids.
[0025] Further aspects of the disclosure relate to nucleic acids encoding the polypeptides described herein. In some aspects, the disclosure relates to cells comprising one or more polypeptides described herein. In some embodiments, the cell further comprises a cancer-specific CAR. In some embodiments, the cancer-specific CAR is a different polypeptide than the TGF-β CAR. In some embodiments, the cancer-specific CAR specifically binds Her2. In some embodiments, the cancer-specific CAR specifically binds CD19 or CD20. In some embodiments, the cancer-specific CAR specifically binds a cancer molecule or antigen known in the art and / or described herein. In some embodiments, the cell is an immune cell. In some embodiments, the cell is a progenitor or stem cell. In some embodiments, the progenitor or stem cell is differentiated in vitro into an immune cell. In some embodiments, the cell is a T cell. In some embodiments, the cell is a CD4+ T cell or a CD8+ T cell. In some embodiments, the cell is a natural killer cell. In some embodiments, the cell is ex vivo. The term immune cell includes cells of the immune system involved in defending the body against both infection and foreign substances. Immune cells may include, for example, neutrophils, eosinophils, basophils, natural killer cells, lymphocytes such as B cells and T cells, and monocytes. T cells may include, for example, CD4+, CD8+, T helper cells, cytotoxic T cells, γδ T cells, regulatory T cells, suppressor T cells, and natural killer T cells. In certain embodiments, the T cells are regulatory T cells.
[0026] A further aspect of the disclosure relates to a method of stimulating an immune response comprising contacting a cell of the disclosure (i.e., a cell comprising an antigen-binding polypeptide described herein) with TGF-β. In some embodiments, stimulating the immune response comprises increasing expression and / or secretion of an immunostimulatory cytokine and / or an immunostimulatory molecule. In some embodiments, the cytokine and / or molecule is a proinflammatory cytokine or molecule. In some embodiments, the immunostimulatory cytokine and / or molecule is one or more of TNF-α, IFN-β, IFN-γ, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-18, and granulocyte-macrophage colony-stimulating factor. In some embodiments, stimulating the immune response comprises increasing proliferation of an immune cell. In some embodiments, the immune cell is a T cell. In some embodiments, the TGF-β is endogenous TGF-β produced in a human subject in need of immune stimulation. In some embodiments, the human subject has cancer, fibrosis, or an open wound. In some embodiments, the human subject has a B-cell malignancy. In some embodiments, the human subject has a solid tumor. A solid tumor is an abnormal mass of tissue that does not usually contain cysts or liquid areas. A solid tumor may be benign (not cancerous) or malignant (cancer). Each type of solid tumor is named based on the type of cells that form the solid tumor. Examples of solid tumors are sarcoma, carcinoma, and lymphoma. In some embodiments, the method is for treating a person with an indication, the indication being characterized by a pathogenic level of TGF-β expression. In some embodiments, the cells and polypeptides described herein may be used to treat cancer, dysregulated wounds, fibrosis, open wounds, solid tumors, etc., where the etiology of the condition is based at least in part on the expression of TGF-β. In some embodiments, the cell (i.e., a cell of the present disclosure comprising an antigen-binding polypeptide) is in a human subject in need of immune stimulation. In some embodiments, the method further comprises administering to the human subject a cell described herein comprising a polypeptide or nucleic acid of the present disclosure.
[0027] Further method aspects relate to methods for detecting TGF-β in a solution comprising contacting a cell of the present disclosure and measuring immune stimulation, where an increase in immune stimulation indicates the presence of TGF-β and no increase in immune stimulation indicates the absence of TGF-β. In some embodiments, the immune stimulation comprises expression of an immune stimulatory cytokine and / or immune stimulatory molecule. In some embodiments, the immune stimulatory cytokine and / or immune stimulatory molecule is one or more of TNF-α, IFN-β, IFN-γ, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-18, and granulocyte macrophage colony stimulating factor. In some embodiments, the immune stimulation comprises increased proliferation of immune cells. In some embodiments, the immune cells are T cells. In some embodiments, the cells are ex vivo.
[0028] The increase in expression or proliferation described herein can be at least, at most, or exactly a 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 50-fold, 100-fold, 200-fold, 300-fold, 500-fold, or 1000-fold increase over a baseline expression level, such as a control (a disease-free control, a non-TGF-β control, or a non-antigen binding polypeptide control).
[0029] Further aspects of the present disclosure relate to methods for producing the polypeptides of the present disclosure comprising expressing in a cell a nucleotide sequence encoding said polypeptide. Further aspects relate to cultured, frozen, suspended, or adherent cells comprising the polypeptides described herein.
[0030] Aspects of the disclosure relate to methods for treating a disease or pathological condition comprising administering to a patient a cell of the disclosure, hi some embodiments, the patient is a human patient.
[0031] In some embodiments, the cell is a regulatory T cell (i.e., a regulatory T cell that comprises a TGF-β binding polypeptide described herein). In some embodiments, the disease is an autoimmune disease. In some embodiments, the autoimmune disease is rheumatoid arthritis. In some embodiments, the autoimmune disease is as described herein.
[0032] In some embodiments of the method aspects, the method further comprises administering TGF-β to the subject.
[0033] In some aspects, the method comprises or further comprises expanding and / or inducing proliferation of T cells in vitro, the method comprising contacting the in vitro T cells of the present disclosure with a composition comprising TGF-β. In some embodiments, the T cells are regulatory cells. In some embodiments, the T cells are T cells described herein. In some embodiments, the expanded regulatory T cells comprise less than 10% non-regulatory T cells. In some embodiments, expanded regulatory T cells comprise less than 0.5%, less than 1%, less than 2%, less than 3%, less than 4%, less than 5%, less than 6%, less than 7%, less than 8%, less than 9%, less than 10%, less than 12%, less than 14%, less than 16%, less than 18%, less than 20%, less than 22%, less than 24%, less than 26%, less than 28%, less than 30%, less than 32%, less than 34%, less than 36%, less than 38%, less than 40%, less than 42%, less than 44%, less than 46%, less than 48%, or less than 50%, or any range derivable therein.
[0034] In some embodiments, the composition comprises 1-50 ng / mL of TGF-β. In some embodiments, the composition comprises at least, at most, or about 0.5 ng / mL, 1 ng / mL, 1.5 ng / mL, 2 ng / mL, 2.5 ng / mL, 3 ng / mL, 3.5 ng / mL, 4 ng / mL, 4.5 ng / mL, 5 ng / mL, 5.5 ng / mL, 6 ng / mL, 6.5 ng / mL, 7 ng / mL, 7.5 ng / mL, 8 ng / mL, 8.5 ng / mL, 9 ng / mL, 10 ng / mL, 11 ng / mL, 12 ng / mL, 13 ng / mL, 14 ng / mL, 15 ng / mL, 16 ng / mL, 17 ng / mL, 18 ng / mL, 19 ng / mL, 20 ng / mL, 21 ng / mL, 22 ng / mL, 23 ng / mL, 24 ng / mL, 25 ng / mL, 26 ng / mL, 27 ng / mL, 28 ng / mL, 29 ng / mL, 30 ng / mL, 31 ng / mL, 32 ng / mL, 33 ng / mL, 34 ng / mL, 35 ng / mL, 36 ng / mL, 37 ng / mL, 38 ng / mL, 39 ng / mL, 40 ng / mL, 41 ng / mL, 42 ng / mL, 43 ng / mL, 44 ng / mL, 45 ng / mL, 46 ng / mL, 47 ng / mL, 48 ng / mL, 49 ng / mL, 50 ng / mL, 5 mL, 17ng / mL, 18ng / mL, 19ng / mL, 20ng / mL, 21ng / mL, 22ng / mL, 23ng / mL, 24ng / mL, 25ng / mL, 30ng / mL, 35ng / mL, 40ng / mL, 45ng / mL, 50ng / mL, 55ng / mL, 60ng / mL, 65ng / mL, 70ng / mL, 75ng / mL, 80ng / mL, 85ng / mL, 90ng / mL, 95ng / mL, or 100ng / mL of TGF-β (or any range derivable therein).
[0035] In some embodiments, the composition further comprises IL-2. In some embodiments, the composition comprises between 20 and 400 U / mL of IL-2.In some embodiments, the composition comprises at least, at most, or about 5 U / mL, 10 U / mL, 15 U / mL, 20 U / mL, 25 U / mL, 30 U / mL, 35 U / mL, 40 U / mL, 45 U / mL, 50 U / mL, 55 U / mL, 60 U / mL, 65 U / mL, 70 U / mL, 75 U / mL, 80 U / mL, 85 U / mL, 90 U / mL, 95 U / mL, 100 U / mL, 105 U / mL, 110 U / mL, 115 U / mL, 120 U / mL, 125 U / mL, 130 U / mL, 135 U / mL, 140 U / mL, 145 U / mL, 150 U / mL , 155U / mL, 160U / mL, 165U / mL, 170U / mL, 175U / mL, 180U / mL, 185U / mL, 190U / mL, 195U / mL, 200U / mL, 205U / mL, 210U / mL, 215U / mL, 220U / mL, 225U / mL, 230 U / mL, 235U / mL, 240U / mL, 245U / mL, 250U / mL, 255U / mL, 260U / mL, 265U / mL, 270U / mL, 275U / mL, 280U / mL, 285U / mL, 290U / mL, 295U / mL, 300U / mL, 305U / mL, 310U / mL, 315U / mL, 320U / mL, 325U / mL, 330U / mL, 335U / mL, 340U / mL, 345U / mL, 350U / mL, 355U / mL, 360U / mL, 365U / mL, 370U / mL, 375U / mL, 380U / mL, 385U / mL, 390U / mL, 395U / mL, 400U / mL, 405U / mL, 410U / mL, 415U / mL, 420U / mL, 425U / mL, 430U / mL, 435U / mL, 440U / mL, 445U / mL, 450U / mL, 455U / mL, 460U / mL, 4 including 65 U / mL, 470 U / mL, 475 U / mL, 480 U / mL, 485 U / mL, 490 U / mL, 495 U / mL, 500 U / mL, 505 U / mL, 510 U / mL, 515 U / mL, 520 U / mL, 525 U / mL, 530 U / mL, 535 U / mL, 540 U / mL, 545 U / mL, 550 U / mL, 555 U / mL, 560 U / mL, 565 U / mL, 570 U / mL, 575 U / mL, 580 U / mL, 585 U / mL, 590 U / mL, 595 U / mL, 600 U / mL of IL-2 (or any range derivable therein).
[0036] In some embodiments, the method further comprises contacting the cells with feeder cells. In some embodiments, the feeder cells are irradiated. Feeder or support cells can include, for example, fibroblasts, mouse fetal fibroblasts, JK1 cells, SNL76 / 7 cells, human fetal skin cells, human fibroblasts, and human foreskin fibroblasts.
[0037] In some embodiments, the method excludes contacting the T cells with feeder cells, which may be from a different animal species than the T cells.
[0038] In one embodiment of the methods described herein, the subject is a human subject. The terms "individual," "subject," "host," and "patient" are used interchangeably herein and refer to mammals, including, but not limited to, murines (e.g., rats, mice), lagomorphs (e.g., rabbits), non-human primates, humans, dogs, cats, ungulates (e.g., horses, cows, sheep, pigs, goats), and the like.
[0039] Before the present invention is further described, it is to be understood that the invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, and the scope of the present invention will be limited only by the appended claims.
[0040] Where a range of values is provided, it is to be understood that each intermediate value between the upper and lower limits of that range (to the nearest tenth of the lower limit unless the context clearly indicates otherwise), and any other stated or intermediate value in that stated range, is encompassed within the scope of the invention. The upper and lower limits of such smaller ranges may be independently included in the smaller range and are encompassed within the scope of the invention, but subject to any limit specifically excluded in the stated range. Where the stated range includes one or both of these limits, ranges excluding either or both of those included limits are also included in the invention.
[0041] [The present invention 1001] A polypeptide comprising a signal peptide, an antigen-binding domain having a heavy chain variable (VH) region and a light chain variable (VL) region, a peptide spacer, a transmembrane domain, and an endodomain, wherein the antigen-binding domain specifically binds to TGF-β. [The present invention 1002] A polypeptide comprising a signal peptide, an antigen-binding domain having a heavy chain variable (VH) region and a light chain variable (VL) region, a peptide spacer, a transmembrane domain, and an endodomain, wherein the VH region comprises SEQ ID NO:5 (HCDR1), SEQ ID NO:6 (HCDR2), and SEQ ID NO:7 (HCDR3), and the VL region comprises SEQ ID NO:8 (LCDR1), SEQ ID NO:9 (LCDR2), and SEQ ID NO:10 (LCDR3). [The present invention 1003] The polypeptide of the present invention, wherein the VH region comprises SEQ ID NO:1 and the VL region comprises SEQ ID NO:2. [The present invention 1004] A polypeptide comprising a signal peptide, an antigen-binding domain having a VH region and a VL region, a peptide spacer, a transmembrane domain, and an endodomain, wherein the VH region comprises SEQ ID NO:11 (HCDR1), SEQ ID NO:12 (HCDR2), and SEQ ID NO:13 (HCDR3), and the VL region comprises SEQ ID NO:14 (LCDR1), SEQ ID NO:15 (LCDR2), and SEQ ID NO:16 (LCDR3). [The present invention 1005] The polypeptide of the present invention, wherein the VH region comprises SEQ ID NO:3 and the VL region comprises SEQ ID NO:4. [The present invention 1006] A polypeptide comprising a signal peptide, an antigen-binding domain having a VH region and a VL region, a peptide spacer, a transmembrane domain, and an endodomain, wherein the VH region comprises SEQ ID NO:21 (HCDR1), SEQ ID NO:22 (HCDR2), and SEQ ID NO:23 (HCDR3), and the VL region comprises SEQ ID NO:24 (LCDR1), SEQ ID NO:25 (LCDR2), and SEQ ID NO:26 (LCDR3). [The present invention 1007] The polypeptide of the present invention, wherein the VH region comprises SEQ ID NO:19 and the VL region comprises SEQ ID NO:20. [The present invention 1008] The polypeptide of any of claims 1001 to 1007, wherein the VH region and the VL region are separated by a peptide linker. [The present invention 1009] The polypeptide of any of claims 1001 to 1008, wherein the polypeptide has a structure of SX-PL-Y-PS-TE or SY-PL-X-SP-TE, wherein S is the signal peptide, X is VH, PL is a peptide linker, Y is VL, PS is the peptide spacer, T is the transmembrane domain, and E is the endodomain. [The present invention 1010] The polypeptide of any one of claims 1001 to 1009, further comprising a costimulatory region. [The present invention 1011] The polypeptide of the present invention, wherein the costimulatory region is between the transmembrane domain and the endodomain. [The present invention 1012] The polypeptide of any one of claims 1001 to 1011, wherein the transmembrane domain comprises the transmembrane domain of CD28. [The present invention 1013] The polypeptide of any of claims 1001 to 1012, wherein the endodomain comprises a CD28 signaling domain or a CD3 zeta signaling domain. [The present invention 1014] The polypeptide of any of claims 1008 to 1013, wherein the peptide linker is a glycine-serine linker. [The present invention 1015] The polypeptide of any of claims 1003 to 1014, wherein the peptide linker is at least 4 amino acids. [The present invention 1016] The polypeptide of any one of claims 1001 to 1015, wherein the endodomain is a CD3 zeta signaling domain. [The present invention 1017] The polypeptide of any of claims 1001 to 1016, wherein the peptide spacer comprises less than 50 amino acids. [The present invention 1018] The polypeptide of any of claims 1001 to 1016, wherein the peptide spacer comprises more than 50 amino acids. [The present invention 1019] The polypeptide of any of claims 1001 to 1018, wherein the peptide spacer comprises a hinge region of an IgG molecule. [The present invention 1020] The polypeptide of any of claims 1001 to 1019, wherein the peptide spacer comprises the hinge region and CH2CH3 region of an IgG molecule. [The present invention 1021] The polypeptide of the present invention, wherein said peptide spacer consists of a hinge region of an IgG molecule. [The present invention 1022] The polypeptide of any one of claims 1001 to 1021, further comprising a detection peptide. [The present invention 1023] The polypeptide of the present invention, wherein the detection peptide is a peptide of SEQ ID NO: 17, 94, or 95. [The present invention 1024] The polypeptide of the present invention 1022 or 1023, wherein the detection peptide is flanked by a linker. [The present invention 1025] The polypeptide of any of claims 1022 to 1024, wherein the detection peptide is N-terminal to the VH domain and the VL domain. [The present invention 1026] The polypeptide of any of claims 1022 to 1025, wherein the detection peptide is located between the signal peptide and the antigen-binding domain. [The present invention 1027] The polypeptide of any one of claims 1001 to 1026, wherein the signal peptide comprises SEQ ID NO:18. [The present invention 1028] The polypeptide of any one of claims 1001 to 1027, further comprising a cancer molecule-specific antigen-binding domain. [The present invention 1029] The polypeptide of the present invention, wherein the cancer molecule comprises Her2. [The present invention 1030] The polypeptide of the present invention, wherein the cancer molecule comprises CD19 or CD20. [The present invention 1031] The polypeptide of any of claims 1002 to 1030, wherein the antigen-binding domain specifically binds to soluble TGF-β. [The present invention 1032] An isolated nucleic acid encoding any one of the polypeptides of the present invention 1001 to 1031. [The present invention 1033] A cell comprising the polypeptide of any one of the present inventions 1001 to 1031 or the nucleic acid of the present invention 1032. [The present invention 1034] The cell of the present invention 1033, further comprising a cancer-specific chimeric antigen receptor (CAR). [The present invention 1035] The polypeptide of the present invention, wherein the cancer-specific CAR specifically binds to Her2. [The present invention 1036] The polypeptide of the present invention, wherein the cancer-specific CAR specifically binds to CD19 or CD20. [The present invention 1037] The cell of the present invention 1036, which is an immune cell. [The present invention 1038] The cell of the present invention 1037, which is a T cell. [The present invention 1039] The cell of the present invention 1038, which is a CD4+ T cell or a CD8+ T cell. [The present invention 1040] The cell of the present invention 1037, which is a natural killer cell. [The present invention 1041] The cell of the present invention, wherein the T cell is a regulatory T cell. [The present invention 1042] A cell according to any one of claims 1033 to 1040, wherein the cell is ex vivo. [The present invention 1043] A method for stimulating an immune response, comprising contacting a cell of any of claims 1033 to 1042 with TGF-β. [The present invention 1044] The method of claim 1043, wherein stimulating the immune response comprises increasing expression and / or secretion of an immunostimulatory cytokine and / or an immunostimulatory molecule. [The present invention 1045] The method of claim 1044, wherein the immune stimulating cytokine and / or immune stimulating molecule is one or more of TNF-α, IFN-β, IFN-γ, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-18, and granulocyte-macrophage colony-stimulating factor. [The present invention 1046] The method of claim 10, wherein stimulating the immune response comprises increasing the proliferation of immune cells. [The present invention 1047] The method of claim 1046, wherein said immune cell is a T cell. [The present invention 1048] The method of any of claims 1043 to 1047, wherein the cell is in vivo in a subject in need of immune stimulation. [The present invention 1049] The method of claim 1048, wherein said TGF-β is endogenous TGF-β produced in said subject in need of immune stimulation. [The present invention 1050] The method of claim 1049, wherein the human subject has cancer, fibrosis, or an open wound. [The present invention 1051] The method of claim 1050, wherein said cancer is melanoma. [The present invention 1052] The method of claim 1049, wherein the human subject has a B-cell malignancy. [The present invention 1053] The method of claim 1049, wherein the human subject has a solid tumor. [The present invention 1054] The method of any of claims 1043 to 1053, further comprising administering said cells to a human subject. [The present invention 1055] The method of any of claims 1047 to 1054, further comprising administering TGF-β to the subject. [The present invention 1056] A method for detecting TGF-β in a solution, comprising contacting a cell of any one of claims 1033 to 1042 with said solution and measuring immune stimulation, wherein an increase in immune stimulation indicates the presence of TGF-β and no increase in immune stimulation indicates the absence of TGF-β. [The present invention 1057] The method of claim 1056, wherein immune stimulation comprises expression of an immune stimulatory cytokine and / or an immune stimulatory molecule. [The present invention 1058] The method of claim 1057, wherein the immune stimulating cytokine and / or immune stimulating molecule is one or more of TNF-α, IFN-β, IFN-γ, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-18, and granulocyte-macrophage colony-stimulating factor. [The present invention 1059] The method of claim 1056, wherein the immune stimulation comprises increasing the proliferation of immune cells. [The present invention 1060] The method of claim 1059, wherein said immune cell is a T cell. [The present invention 1061] The method of any one of claims 1056 to 1060, wherein the cell is ex vivo. [The present invention 1062] A method for producing any one of the polypeptides of present inventions 1001 to 1031, comprising expressing a nucleotide encoding the polypeptide in a cell. [The present invention 1063] A method for in vitro proliferation of T cells, the method comprising contacting an in vitro T cell of any of claims 1038 to 1041 with a composition comprising TGF-β. [The present invention 1064] The method of claim 1063, wherein the composition contains 1 to 50 ng / mL of TGF-β. [The present invention 1065] The method of any one of claims 1063 to 1064, wherein the composition further comprises IL-2. [The present invention 1066] The method of claim 1065, wherein the composition contains 20 to 400 U / mL of IL-2. [The present invention 1067] The method of any of claims 1063 to 1066, further comprising contacting said cells with feeder cells. [The present invention 1068] The method of claim 1067, wherein said feeder cells are irradiated. [The present invention 1069] The method according to any one of claims 1063 to 1066, wherein contact of said T cells with feeder cells is omitted. [The present invention 1070] The method of any of claims 1063 to 1069, wherein the T cells are regulatory T cells. [The present invention 1071] The method of claim 1070, wherein said expanded regulatory T cells comprise less than 10% non-regulatory T cells. [The present invention 1072] A method for treating a disease or pathological condition in a patient, the method comprising administering to the patient a cell of any of claims 1038 to 1042 of the present invention. [The present invention 1073] The method of claim 1072, wherein the cell is a regulatory T cell. [The present invention 1074] The method of claim 1073, wherein the disease is an autoimmune disease. [The present invention 1075] The method of claim 1072, wherein the disease is cancer. [The present invention 1076] The method of any of claims 1072 to 1075, further comprising expanding said cells in vitro by a method comprising contacting said cells in vitro with a composition comprising TGF-β. [The present invention 1077] The method of claim 1076, wherein the composition comprises 1 to 50 ng / mL of TGF-β. [The present invention 1078] The method of any one of claims 1076 to 1077, wherein the composition further comprises IL-2. [The present invention 1079] The method of claim 1078, wherein the composition contains 20 to 400 U / mL of IL-2. [The present invention 1080] The method of any of claims 1076 to 1079, further comprising contacting said cells with feeder cells. [The present invention 1081] The method of claim 1080, wherein said feeder cells are irradiated. [The present invention 1082] The method according to any one of claims 1076 to 1079, wherein contact of said T cells with feeder cells is omitted. [The present invention 1083] The method of any of claims 1076 to 1082, wherein the T cells are regulatory T cells. [The present invention 1084] The method of claim 1083, wherein said expanded regulatory T cells comprise less than 10% non-regulatory T cells. [The present invention 1085] The method of any one of claims 1074 and 1076 to 1084, wherein the autoimmune disease is rheumatoid arthritis. [The present invention 1086] The method of any of claims 1072 to 1085, further comprising administering TGF-β to said patient. Other objects, features and advantages of the present invention will become apparent from the following detailed description, but it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given for illustrative purposes only, since various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description. [Brief description of the drawings]
[0042] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0043] [Figure 1] Figure 1 shows that TGF-β scFv neutralizes human TGF-β. The indicated amounts of TGF-β and anti-TGF-β scFv were added to cultures of HepG2 cells for 30 min. Neutralization of TGF-β is shown by a decrease in phosphorylated SMAD2 response detected by Western blot. [Diagram 2]We show that TGF-β CAR is expressed on the cell surface. TGF-β CAR was generated using scFv#2. Surface staining and flow cytometry show that TGF-β CAR is displayed on the cell surface of CD4+ and CD8+ T cells. The extracellular domain of the receptor contains the FLAG epitope. EGFRt is a truncated epidermal growth factor receptor, which indicates cell transduction. [Diagram 3] Figures 3A-B show that TGF-β CAR blocks endogenous TGF-β signaling in (A) CD8+ and (B) CD4+ T cells. Expression of TGF-β CAR in T cells blocks TGF-β signaling through the SMAD pathway. T cells expressing the indicated receptors were incubated with TGF-β for 30 min and probed by Western blot for phosphorylated SMAD2. No scFv represents a CAR without any ligand (antigen) binding scFv domain, and EGFRt represents a truncated epidermal growth factor receptor independent of other components herein. [Figure 4](A) Jurkat cells stably expressing a TGF-β CAR and an NFAT reporter (EGFP expressed from an NFAT inducible promoter) show increased activation in response to increasing TGF-β concentrations. (B, C) Primary human CD4+ T cells stably expressing a TGF-β CAR upregulate (B) CD69 expression and (C) Th1 cytokine production in response to TGF-β stimulation. CD69 upregulation was monitored by surface staining after 1 day of incubation with or without TGF-β. Cytokine production was detected by applying the protein transport inhibitor brefeldin A and performing intracellular staining after 1 day of incubation with or without TGF-β. "Mock" represents T cells transduced with an irrelevant construct. "No scFv" represents T cells expressing a CAR identical to the TGF-β CAR except that it does not have the scFv domain and therefore cannot bind TGF-β. "DNR" is dominant negative TGF-β receptor, which is a truncated TGF-β receptor chain 2 lacking the cytoplasmic signaling domain. Values presented are the mean of triplicates with error bars indicating ±1 standard deviation (std). *p<0.05, **p<0.005, ***p<0.0005, **** *p≦0.0005. [Diagram 5] It shows that dominant-negative TGF-β receptors cannot induce the production of cytokines. Dominant-negative TGF-β receptors have also been reported to inhibit TGF-β signaling, but do not induce immunostimulatory effects such as the production of TNF-α. Tβ short and Tβ long are two different types of TGF-β CARs, Dom-Neg represents a dominant-negative TGF-β receptor, and No scFv represents a CAR without any ligand-binding scFv domain. Tβ short represents a TGF-β CAR polypeptide with a peptide spacer consisting of only the IgG4 hinge region. Tβ long represents a TGF-β CAR polypeptide with a peptide spacer including the IgG4 hinge region and the CH2CH3 region. [Figure 6]1 shows that TGF-β CAR-T cells proliferate in response to TGF-β. [Figure 7] Figure 1 shows inhibition of mouse TGF-β / SMAD signaling. The indicated amounts of scFv and mouse TGF-β1 were applied to NIH3T3 fibroblasts for 30 minutes. Cells were lysed and probed for SMAD2 phosphorylation. [Figure 8] Jurkat cells stably expressing a TGF-β CAR and an NFAT reporter (EGFP expressed from an NFAT-inducible promoter) showed increased activation in response to increasing inputs of mouse TGF-β1, indicating that a TGF-β CAR engineered to recognize human TGF-β also cross-reacts with mouse TGF-β. [Figure 9] TGF-β CARs are expressed on the cell surface more efficiently than dominant-negative TGF-β receptors. [Figure 10] The function of the TGF-β CAR can be modulated by the choice of costimulatory domain. [Figure 11] TGF-β consistently induces the production of TNF-α in a dose-dependent manner across cells from different donors. [Figure 12] The peptide spacer length of TGF-β CAR modulates the induction threshold. [Figure 13] CAR signaling requires ligand-mediated CAR dimerization, but does not require that the ligand or the CAR itself pre-exist as a dimer. CD69 surface staining was performed on Jurkat cell lines carrying the indicated CARs. Both GFP CAR#1 and GFP CAR#3 exist primarily as homodimers, and these two CARs bind different epitopes on EGFP and can simultaneously bind to monomeric EGFP molecules. GFP CAR#1 and GFP CAR#2 bind the same epitope on EGFP, but CAR#2 exists as a monomer rather than a homodimer. [Figure 14] Soluble dimeric antigen molecules can induce signal transduction by ligating receptors on different cells. [Figure 15] TGF-β CAR can be induced in a cell-contact-dependent and -independent manner. [Figure 16] TGF-β CAR-T cells can be activated even in the absence of cell-to-cell contact. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0044] Description of exemplary embodiments The polypeptides, cells, and methods described herein can be used to neutralize TGF-β and specifically induce T cell activation in the presence of TGF-β.
[0045] I. Definition The peptides of the present disclosure relate to peptides that contain CAR, i.e. chimeric antigen receptor. CAR is an engineered receptor that confers arbitrary specificity to immune effector cells. These receptors are commonly used to confer the specificity of monoclonal antibodies to T cells. This receptor is called chimeric because it is composed of parts from different sources.
[0046] The terms "protein," "polypeptide," and "peptide" are used interchangeably herein when referring to gene products.
[0047] "Homology", "identity" or "similarity" refers to the degree of sequence similarity between two peptides or two nucleic acid molecules. Identity can be calculated by comparing a position in each sequence that can be aligned for comparison purposes. If a position in the compared sequences is occupied by the same base or amino acid, the molecules share sequence identity at that position. The degree of identity between sequences is a function of the number of matching or homologous positions shared by the sequences. An "unrelated" or "non-homologous" sequence is one that shares less than 40% identity or less than 25% identity with one of the sequences of the present disclosure.
[0048] The terms "amino moiety," "N-terminus," "amino terminus," and the like, as used herein, are used to refer to the order of a region of a polypeptide. Furthermore, when it is N-terminal to a region, it does not necessarily mean that it is at the end (or terminal) of the entire polypeptide, but simply that it is at the end of the region or domain. Similarly, the terms "carboxy moiety," "C-terminus," "carboxy terminus," and the like, as used herein, are used to refer to the order of a region of a polypeptide, and when it is C-terminal to a region, it does not necessarily mean that it is at the end (or terminal) of the entire polypeptide, but simply that it is at the end of the region or domain.
[0049] The terms "polynucleotide", "nucleic acid", and "oligonucleotide" are used interchangeably and refer to a polymeric form of nucleotides (deoxyribonucleotides or ribonucleotides, or analogs thereof) of any length. Polynucleotides can have any three-dimensional structure and perform any function, known or unknown. Non-limiting examples of polynucleotides include genes or gene fragments (e.g., probes, primers, ESTs, or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, dsRNA, siRNA, miRNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and nucleic acid primers. Polynucleotides can include modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure can be applied before or after assembly of the polynucleotide. The sequence of nucleotides can be interrupted by non-nucleotide components. Polynucleotides can be further modified after polymerization, for example, by conjugation with a labeling component. The term also refers to both double-stranded and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention that is a polynucleotide includes the double-stranded form and each of the two complementary single-stranded forms that are known or predicted to constitute the double-stranded form.
[0050] The terms "subject," "individual," or "patient" are used interchangeably herein and refer to a vertebrate, such as a primate, a mammal, or preferably a human. Mammals include, but are not limited to, horses, dogs, cows, sheep, mice, rats, monkeys, humans, farm animals, sport animals, and pets.
[0051] The terms "xeno-free (XF)", "animal component-free (ACF)" or "animal-free", when used in reference to a medium, extracellular matrix, or culture condition, refer to a medium, extracellular matrix, or culture condition that is essentially free of xenogeneic animal-derived components. When culturing human cells, any protein from a non-human animal, such as a mouse, would be a xenogeneic component. In certain aspects, the xeno-free matrix is essentially free of any non-human animal-derived components, and therefore excludes mouse feeder cells or Matrigel™. Matrigel™ is a soluble basement membrane preparation extracted from the EHS (Engelbreth-Holm-Swarm) mouse sarcoma, a tumor rich in extracellular matrix proteins, including laminin (major component), collagen IV, heparin sulfate proteoglycan, and entactin / nidogen. In some embodiments, the compositions described herein or the cells of the present disclosure are cultured and / or prepared in xeno-free medium, or animal component-free medium, or animal-free medium.
[0052] As used herein, cells are "substantially free" of a particular reagent or element, such as serum, signaling inhibitors, animal components or feeder cells, exogenous genetic elements, or vector elements, if they have less than 10% of that element, and are "essentially free" of a particular reagent or element if they have less than 1% of that element. However, even more desirable are cell populations in which less than 0.5% or less than 0.1% of the total cell population contains exogenous genetic elements or vector elements.
[0053] A culture medium, matrix, or media is "substantially free" of a particular reagent or component (serum, signal transduction inhibitors, animal components, or feeder cells) if the culture medium, matrix, or media contains levels of these reagents below detectable levels using conventional detection methods known to those of skill in the art, respectively, or if these reagents are not added exogenously to the culture medium, matrix, or media. Serum-free media may be essentially free of serum.
[0054] A "gene," "polynucleotide," "coding region," "sequence," "segment," "fragment," or "transgene" that "encodes" a particular protein is a nucleic acid molecule that is transcribed in vitro or in vivo and, optionally, translated into a gene product (e.g., a polypeptide) when placed under the control of appropriate regulatory sequences. The coding region may be present in either cDNA, genomic DNA, or RNA form. If the nucleic acid molecule is present in DNA form, it may be single-stranded (i.e., the sense strand) or double-stranded. The boundaries of the coding region are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A gene may include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and synthetic DNA sequences. A transcription termination sequence will typically be located 3' to the gene sequence.
[0055] The term "cell" is used herein in its broadest sense in the art to refer to a living organism, which is a structural unit of tissue in a multicellular organism, surrounded by an insulating membrane structure, capable of self-replication, and which contains genetic information and mechanisms for expressing it. As used herein, a cell can be a naturally occurring cell or an artificially modified cell (e.g., a fusion cell, a genetically modified cell, etc.).
[0056] As used herein, the term "stem cell" refers to a cell that can self-renew and has pluripotency or multipotency. Typically, stem cells can regenerate damaged tissue. The stem cell in this specification can be, but is not limited to, embryonic stem (ES) cells, induced pluripotent stem cells, or tissue stem cells (also referred to as tissue-specific stem cells or somatic stem cells).
[0057] "Embryonic stem (ES) cells" are pluripotent stem cells derived from early embryos. ES cells were first established in 1981, and have been used to create knockout mice since 1989. Human ES cells were established in 1998, and are now available for use in regenerative medicine.
[0058] Unlike ES cells, tissue stem cells have limited differentiation potential. Tissue stem cells exist in specific locations in tissues and have undifferentiated intracellular structures. Therefore, tissue stem cells generally have low pluripotency. Tissue stem cells have a high nucleus / cytoplasm ratio and few intracellular organelles. Many tissue stem cells have low pluripotency, a long cell cycle, and proliferation potential for more than an individual's lifetime. Based on the site from which the cells originate, tissue stem cells are classified into skin system, digestive system, bone marrow system, nervous system, etc. Skin system tissue stem cells include epidermal stem cells and hair follicle stem cells. Digestive system tissue stem cells include pancreatic (common) stem cells and hepatic stem cells. Bone marrow system tissue stem cells include hematopoietic stem cells and mesenchymal stem cells. Nervous system tissue stem cells include neural stem cells and retinal stem cells.
[0059] "Induced pluripotent stem cells", commonly abbreviated as iPS cells or iPSCs, refer to a type of pluripotent stem cell that is artificially prepared from non-pluripotent cells, typically adult somatic cells or terminally differentiated cells (such as fibroblasts, hematopoietic cells, muscle cells, neurons, or epidermal cells), by introducing specific factors called reprogramming factors.
[0060] "Pluripotent" refers to a stem cell that has the potential to differentiate into all cells that make up one or more tissues or organs, or in particular into any of the three germ layers: endoderm (stomach lining, gastrointestinal tract, lungs), mesoderm (muscle, bone, blood, urogenital tract), or ectoderm (epidermal tissue and nervous system). As used herein, "pluripotent stem cell" refers to a cell that can differentiate into cells derived from any of the three germ layers (e.g., the direct descendants of a totipotent cell or an induced pluripotent cell).
[0061] As used herein, the terms "treatment" and "treating" refer to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic in that it completely or partially prevents a disease or a symptom of the disease, and / or it may be therapeutic in that it partially or completely cures a disease and / or a deleterious effect caused by the disease. As used herein, "treatment" includes any treatment of a disease in a mammal (e.g., a human), and "treatment" includes (a) preventing the disease from occurring in a subject who may be infected with the disease but has not yet been diagnosed as suffering from the disease, (b) inhibiting the disease, i.e., preventing its development, and (c) alleviating the disease, i.e., causing regression of the disease.
[0062] In some embodiments, the methods are useful for reducing the size and / or cell number of a solid tumor. In some embodiments, the methods of the present disclosure are useful for inhibiting the growth of a tumor, such as a solid tumor, in a subject.
[0063] The term "antigen" refers to any substance against which the immune system produces antibodies or against which T cells respond. In some embodiments, an antigen is a peptide that is 5-50 amino acids in length, or at least, at most, or exactly 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, or 300 amino acids, or any range obtainable therein.
[0064] The term "antibody" includes monoclonal antibodies, polyclonal antibodies, dimeric, multimeric, multispecific antibodies, and antibody fragments, which may be human, murine, humanized, chimeric, or derived from another species. A "monoclonal antibody" is an antibody obtained from a population of substantially homogeneous antibodies directed against a specific antigenic site.
[0065] "Antibody or functional fragment thereof means an immunoglobulin molecule that specifically binds to or immunologically reacts with a particular antigen or epitope, and includes polyclonal and monoclonal antibodies. The term antibody includes recombinant or modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies (e.g., bispecific antibodies, diabodies, triabodies, and tetrabodies). The term functional antibody fragment includes antigen-binding fragments of antibodies, including, for example, Fab' fragments, F(ab')2 fragments, Fab fragments, Fv fragments, rlgG fragments, and scFv fragments. The term scFv refers to a single chain Fv antibody in which the heavy chain variable domain and the light chain variable domain of a conventional two-chain antibody are combined to form a single chain.
[0066] Of particular interest is the use of single chain variable fragments (scFv). scFv are recombinant molecules in which the variable regions of the heavy and light immunoglobulin chains that encode the antigen-binding domain have been engineered into a single polypeptide chain. H Arrays and V L The sequences are linked by a linker sequence. See, e.g., Ahmad (2012) Clinical and Developmental Immunology Article ID 980250, which is specifically incorporated by reference herein.
[0067] "Therapeutically effective amount" or "effective amount" means the amount of an agent, or the amount of two agents combined, that when administered to a mammal or other subject for treating a disease is sufficient to affect such treatment for the disease. A "therapeutically effective amount" will vary depending on the agent, the disease and its severity, and the age, weight, etc., of the subject being treated.
[0068] As used herein, "a" or "an" may mean one or more. As used in the claims herein, the words "a" or "an", when used in conjunction with the word "comprising", may mean one or more than one.
[0069] Although the term "or" in the claims is used to mean "and / or" unless expressly indicated to refer only to alternatives or that the alternatives are mutually exclusive, the present disclosure supports a definition that means only alternatives and "and / or." As used herein, "another" may mean at least a second or more.
[0070] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, method being employed to determine the value, or the variation that exists among testing subjects.
[0071] II. Polypeptides A. Signal Peptides "Signal peptide" refers to a peptide sequence that directs the transport and localization of intracellular proteins, e.g., to a specific organelle (such as the endoplasmic reticulum) and / or to the cell surface. The signal peptide directs the nascent protein into the endoplasmic reticulum. This is essential if the receptor is to be glycosylated and anchored to the cell membrane. It is common to use a signal peptide that is often naturally attached to the amino-terminal portion (e.g., in an scFv with the order light chain-linker-heavy chain, the natural signal peptide of the light chain is used). In some embodiments, the signal peptide is SEQ ID NO:18.
[0072] In some embodiments, the signal peptide is one that is cleaved after passage through the endoplasmic reticulum (ER), i.e., a cleavable signal peptide, hi some embodiments, a restriction enzyme site is at the carboxy terminus of the signal peptide to facilitate cleavage.
[0073] B. Antigen-binding Domains The antigen-binding domain is a single-chain variable fragment (scFv) based on the TGF-β antibody. A "single-chain Fv" or "scFv" antibody fragment is an antibody fragment that is a single-chain variable fragment of an antibody. H Domain and V L and a V domain, wherein the domains are in a single polypeptide chain. In some embodiments, the antigen-binding domain comprises a V H Domain and V L It further contains a peptide linker between the domains which enables the scFv to form the desired structure for antigen binding.
[0074] The variable regions of the antigen-binding domain of the polypeptide of the present disclosure can be modified by mutating amino acid residues in the CDR1, CDR2 and / or CDR3 regions of the VH and / or VL to improve one or more binding properties (e.g., affinity) of the antibody. The term "CDR" refers to complementarity determining regions, which are based on portions of the variable chains of immunoglobulins (antibodies) and T cell receptors produced by B cells and T cells, respectively, that bind these molecules to specific antigens. Much of the sequence diversity associated with immunoglobulins and T cell receptors is found in the CDRs, and these regions are sometimes referred to as hypervariable regions. Mutations can be introduced by site-directed or PCR-mediated mutagenesis, and their effect on antibody binding or other functional properties of interest can be evaluated in suitable in vitro or in vivo assays. Conservative modifications are preferred, typically changing no more than one, two, three, four or five residues in the CDR regions. Mutations can be amino acid substitutions, additions, or deletions.
[0075] Framework modifications can be made to the antibody to reduce immunogenicity, e.g., by "backmutating" one or more framework residues to the corresponding germline sequence.
[0076] An antigen-binding domain could also be made multispecific or multivalent by multimerizing the antigen-binding domain with VH and VL domain pairs that bind the same antigen (multivalent) or different antigens (multispecific).
[0077] As used herein, the term "affinity" refers to the equilibrium constant of reversible binding of two agents, expressed as a dissociation constant (Kd). The affinity can be at least 1-fold greater, at least 2-fold greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater, at least 20-fold greater, at least 30-fold greater, at least 40-fold greater, at least 50-fold greater, at least 60-fold greater, at least 70-fold greater, at least 80-fold greater, at least 90-fold greater, at least 100-fold greater, or at least 1000-fold greater, or more (or any range therein). As used herein, the term "binding activity" refers to the resistance of a complex of two or more agents to dissociation after dilution. The terms "immunoreactive" and "preferentially bind" are used interchangeably herein with respect to antibodies and / or antigen-binding fragments.
[0078] The term "bonded" refers to a direct association between two molecules, for example, by covalent, electrostatic, hydrophobic, and ionic bonds, and / or hydrogen bonding interactions (including interactions such as salt bridges and water bridges).
[0079] C. Peptide Spacers The spacer region connects the antigen-binding domain to the transmembrane domain. This region should be flexible enough to allow the antigen-binding domain to be oriented in various directions to facilitate antigen recognition. The most basic form is a hinge region from IgG. Others include the CH2CH3 region of immunoglobulins and parts of CD3. In some embodiments, the CH2CH3 region may have an L235E / N297Q modification or an L235D / N297Q modification, or may have at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity of the CH2CH3 region. An IgG hinge is sufficient for most scFv-type constructs. However, the best spacer must often be determined empirically. In some embodiments, the spacer is from IgG4.
[0080] As used herein, the term "hinge" refers to a flexible polypeptide connector region (also referred to as a "hinge region" or "spacer") that provides structural flexibility and spacing to adjacent polypeptide regions and can be composed of natural or synthetic polypeptides. The "hinge" from an immunoglobulin (e.g., IgG1) is generally defined as the section from Glu216 to Pro230 of human IgG1 (Burton (1985) Molec. Immunol., 22:161-206). Hinge regions of other IgG isotypes can be aligned with the IgG1 sequence by positioning the first and last cysteine residues to form inter-heavy chain disulfide (SS) bonds at the same positions. Hinge regions can be naturally or non-naturally occurring, including, but not limited to, modified hinge regions described in U.S. Pat. No. 5,677,425. The hinge region may include a complete hinge region derived from an antibody of a class or subclass different from that of the CH1 domain. The term "hinge" may also include regions derived from CD8 and other receptors that serve a similar function in providing flexibility and spacing to adjacent regions.
[0081] The peptide spacer may be at least, at most, or exactly 4, 5, 6, 7, 8, 9, 10, 15, 16, 17, 18, 19, 20, 20, 25, 30, 35, 40, 45, 50, 75, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273 The peptide spacer may have a length of 5, 216, 217, 218, 219, 220, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 260, 270, 280, 290, 300, 325, 350, or 400 amino acids (or any range derivable therein). In some embodiments, the peptide spacer consists of or comprises a hinge region from an immunoglobulin. The amino acid sequences of immunoglobulin hinge regions are known in the art, see, e.g., Tan et al. (1990) Proc. Natl. Acad. Sci. USA 87:162; and Huck et al. (1986) Nucl. Acids Res.
[0082] The length of the peptide spacer can affect the response to TGF-β and / or growth characteristics, in some embodiments, a short spacer, such as less than 50, less than 45, less than 40, less than 30, less than 35, less than 30, less than 25, less than 20, less than 15, or less than 10 amino acids, can have the advantage of reducing the concentration of TGF-β required for an effective activation response. In some embodiments, at least 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 225, 226, 227, 228 Longer spacers, such as spacers of 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 260, 270, 280, or 290 amino acids, may have the advantage of increasing proliferation in vivo or in vitro.
[0083] As a non-limiting example, an immunoglobulin hinge region can include one of the following amino acid sequences: TIFF2024155943000001.tif48166 In some embodiments, the hinge is SEQ ID NO:98 or SEQ ID NO:99. In some embodiments, the hinge is SEQ ID NO:99.
[0084] The hinge region may comprise the amino acid sequence of a human IgG1, IgG2, IgG3, or IgG4 hinge region. The hinge region may contain one or more amino acid substitutions and / or insertions and / or deletions compared to a wild-type (naturally occurring) hinge region. For example, His229 of the human IgG1 hinge may be replaced by Tyr, such that the hinge region has the sequence It will contain TIFF2024155943000002.tif4128.
[0085] The hinge region can comprise an amino acid sequence derived from human CD8, for example, the hinge region can comprise the following amino acid sequence: TIFF2024155943000003.tif5154 or its variants.
[0086] D. Transmembrane Domain The transmembrane domain is a hydrophobic alpha helix that spans the membrane. Typically, the transmembrane domain is taken from the most membrane-proximal component of the endodomain. Different transmembrane domains result in different receptor stabilities.
[0087] The transmembrane domain is inserted between the peptide spacer and the endodomain. In some embodiments, the transmembrane domain is inserted between the peptide spacer and the costimulatory region. In some embodiments, a linker is between the transmembrane domain and the costimulatory region or the endodomain.
[0088] Suitable for use is any transmembrane domain that allows a polypeptide to be inserted into the cell membrane of a eukaryotic (e.g., mammalian) cell. Non-limiting examples include transmembrane sequences TIFF2024155943000004.tif4128 may be used. In some embodiments, the transmembrane domain is derived from CD8 beta. TIFF2024155943000005.tif4128, CD4-derived TIFF2024155943000006.tif4128, derived from CD3 Zeta TIFF2024155943000007.tif4128, CD28 derived TIFF2024155943000008.tif4128, CD134(OX40) derived TIFF2024155943000009.tif4128, or CD7-derived The file is TIFF2024155943000010.tif4128.
[0089] E. Endodomain After recognizing antigen, the receptors cluster and a signal is transmitted to the cell via the endodomain and / or the costimulatory domain. In some embodiments, the costimulatory domain described herein is a part of the endodomain. The most commonly used endodomain component is CD3 zeta, which contains three ITAMs. It transmits activation signals to T cells after antigen binding. CD3 zeta cannot provide a fully competent activation signal and further costimulatory signaling is required. For example, chimeric CD28 and OX40 can be used with CD3 zeta to transmit proliferation / survival signals, or all three can be used together.
[0090] Additional endodomains suitable for use in the polypeptides of the present disclosure include any desired signaling domain that provides a characteristic, detectable signal (e.g., increased production of one or more cytokines by a cell, changes in transcription of a target gene, changes in activity of a protein, changes in cell behavior (e.g., cell death), cell proliferation, cell differentiation, cell survival, modulation of an intracellular signaling response, etc.) upon activation via binding of an antigen to the antigen-binding domain. In some embodiments, the endodomain includes at least one (e.g., one, two, three, four, five, six, etc.) ITAM motif described herein. In some embodiments, the endodomain includes a DAP10 / CD28-type signaling chain.
[0091] Suitable endodomains for use in the polypeptides of the present disclosure include intracellular signaling polypeptides that contain an immunoreceptor tyrosine-based activation motif (ITAM). An ITAM motif is YX1X2(L / I), where X1 and X2 are independently any amino acid (SEQ ID NO:64). An endodomain may contain one, two, three, four, or five ITAM motifs. In some cases, an ITAM motif is repeated twice within an endodomain, with the first and second instances of the ITAM motif separated from each other by 6-8 amino acids, e.g., (YX1X2(L / I))(X3). n (YX1X2(L / I)), where n is an integer from 6 to 8, and each of the 6 to 8 X3 can be any amino acid (SEQ ID NO:65).
[0092] A suitable endodomain may be an ITAM motif-containing portion derived from a polypeptide containing an ITAM motif. For example, a suitable endodomain may be an ITAM motif-containing domain derived from any ITAM motif-containing protein. Thus, a suitable endodomain does not need to contain the entire sequence of the entire protein from which it is derived. Examples of suitable ITAM motif-containing polypeptides include, but are not limited to, DAP12, FCER1G (Fc epsilon receptor I gamma chain), CD3D (CD3 delta), CD3E (CD3 epsilon), CD3G (CD3 gamma), CD3Z (CD3 zeta), and CD79A (antigen receptor complex-associated protein alpha chain).
[0093] The endodomain may be derived from DAP12 (also known as TYROBP, TYRO protein tyrosine kinase binding protein, KARAP, PLOSL, DNAX activating protein 12, KAR associated protein, TYRO protein tyrosine kinase binding protein, killer activating receptor associated protein, killer activating receptor associated protein, etc.). For example, a suitable endodomain polypeptide is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000011.tif70166.
[0094] In some embodiments, a suitable endodomain polypeptide may comprise an ITAM motif-containing portion of the full-length DAP12 amino acid sequence. Thus, a suitable endodomain polypeptide may comprise: It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000012.tif4128.
[0095] In some embodiments, the endodomain is derived from FCER1G (also known as FCRG, Fc epsilon receptor I gamma chain, Fc receptor gamma chain, fc epsilon Rl gamma, fcR gamma, fceRI gamma, high affinity immunoglobulin epsilon receptor subunit gamma, high affinity gamma chain of the immunoglobulin E receptor, etc.). For example, a suitable endodomain polypeptide is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000013.tif12159.
[0096] In some embodiments, a suitable endodomain polypeptide may comprise an ITAM motif-containing portion of the full-length FCER1G amino acid sequence. Thus, a suitable endodomain polypeptide may comprise: It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000014.tif4128.
[0097] In some embodiments, the endodomain is derived from the T cell surface glycoprotein CD3 delta chain (also known as CD3D, CD3-DELTA, T3D, delta subunit of the CD3 antigen, CD3 delta, delta polypeptide of the CD3d antigen (TiT3 complex), delta chain of OKT3, T cell receptor T3 delta chain, T cell surface glycoprotein CD3 delta chain, etc.). For example, a suitable endodomain polypeptide may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to a contiguous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 170 aa of any of the following amino acid sequences (two isoforms): TIFF2024155943000015.tif48160.
[0098] In some embodiments, a suitable endodomain polypeptide may comprise an ITAM motif-containing portion of the full-length CD3 delta amino acid sequence. Thus, a suitable endodomain polypeptide may comprise: It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000016.tif4128.
[0099] In some embodiments, the endodomain is derived from the T cell surface glycoprotein CD3 epsilon chain (also known as CD3e, T cell surface antigen T3 / Leu-4 epsilon chain, T cell surface glycoprotein CD3 epsilon chain, AI504783, CD3, CD3 epsilon, T3e, etc.). For example, a suitable endodomain polypeptide may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to a contiguous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 205 aa of the following amino acid sequences: TIFF2024155943000017.tif26160.
[0100] In some embodiments, a suitable endodomain polypeptide may comprise an ITAM motif-containing portion of the full-length CD3 epsilon amino acid sequence. Thus, a suitable endodomain polypeptide may comprise: It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000018.tif5128.
[0101] In some embodiments, the endodomain is derived from the T cell surface glycoprotein CD3 gamma chain (also known as CD3G, T cell receptor T3 gamma chain, CD3-GAMMA, T3G, gamma polypeptide (TiT3 complex), etc.). For example, a suitable endodomain polypeptide may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to a contiguous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 180 aa of the following amino acid sequences: TIFF2024155943000019.tif26160.
[0102] In some embodiments, a suitable endodomain polypeptide may comprise an ITAM motif-containing portion of the full-length CD3 gamma amino acid sequence. Thus, a suitable endodomain polypeptide may comprise: It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000020.tif4128.
[0103] In some embodiments, the endodomain is derived from the T cell surface glycoprotein CD3 zeta chain (also known as CD3Z, T cell receptor T3 zeta chain, CD247, CD3 zeta, CD3H, CD3Q, T3Z, TCRZ, etc.). For example, a suitable intracellular signaling domain polypeptide can comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to a contiguous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 140 aa, about 140 aa to about 150 aa, or about 150 aa to about 160 aa of any of the following amino acid sequences (two isoforms): TIFF2024155943000021.tif56160.
[0104] In some embodiments, a suitable endodomain polypeptide may comprise an ITAM motif-containing portion of the full-length CD3 zeta amino acid sequence. Thus, a suitable endodomain polypeptide may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to any of the following amino acid sequences: TIFF2024155943000022.tif34160.
[0105] In some embodiments, the endodomain is derived from CD79A (also known as B-cell antigen receptor complex-associated protein alpha chain, CD79a antigen (immunoglobulin-associated alpha), MB-1 membrane glycoprotein, ig alpha, membrane-associated immunoglobulin-associated protein, surface IgM-associated protein, etc.). For example, a suitable endodomain polypeptide may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to a contiguous stretch of about 100 amino acids to about 110 amino acids (aa), about 110 aa to about 115 aa, about 115 aa to about 120 aa, about 120 aa to about 130 aa, about 130 aa to about 150 aa, about 150 aa to about 200 aa, or about 200 aa to about 220 aa of any of the following amino acid sequences (two isoforms): TIFF2024155943000023.tif63161.
[0106] In some embodiments, a suitable endodomain polypeptide may comprise an ITAM motif-containing portion of the full-length CD79A amino acid sequence. Thus, a suitable endodomain polypeptide may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to the following amino acid sequence: TIFF2024155943000024.tif5128.
[0107] In some embodiments, a suitable endodomain may comprise a DAP10 / CD28 type signaling chain. One example of a DAP10 signaling chain has the amino acid sequence: TIFF2024155943000025.tif4128. In some embodiments, a suitable endodomain has the amino acid sequence It contains an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% amino acid sequence identity to the full length of TIFF2024155943000026.tif4128.
[0108] An example of the CD28 signaling chain is the amino acid sequence TIFF2024155943000027.tif12158. In some embodiments, a suitable endodomain has the amino acid sequence It contains an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% amino acid sequence identity to the full length of TIFF2024155943000028.tif12158.
[0109] Additional endodomains suitable for use in the polypeptides of the disclosure include ZAP70 polypeptides, e.g., polypeptides that include an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% amino acid sequence identity to a contiguous stretch of from about 300 amino acids to about 400 amino acids, from about 400 amino acids to about 500 amino acids, or from about 500 amino acids to about 619 amino acids of the following amino acid sequences: TIFF2024155943000029.tif85160.
[0110] F. Detection Peptides Suitable detection peptides include hemagglutinin (HA, e.g. TIFF2024155943000030.tif4128), FLAG (e.g., TIFF2024155943000031.tif4128), c-myc (e.g., TIFF2024155943000032.tif4128), etc. Other suitable detection peptides are known in the art.
[0111] G. Peptide Linkers In some embodiments, the polypeptides of the present disclosure include a peptide linker (sometimes referred to as a linker). The peptide linker may separate any of the peptide domains / regions described herein. By way of example, the linker may be between the signal peptide and the antigen binding domain, between the VH and VL of the antigen binding domain, between the antigen binding domain and the peptide spacer, between the peptide spacer and the transmembrane domain (adjacent to the costimulatory region or in the N or C region of the costimulatory region), and / or between the transmembrane domain and the endodomain. The peptide linker may have any of a variety of amino acid sequences. The domains and regions may be linked by peptide linkers, which are generally flexible in nature, but do not exclude other chemical bonds. The linker may be a peptide of about 6 to about 40 amino acids in length, or a peptide of about 6 to about 25 amino acids in length. These linkers may be produced using synthetic oligonucleotides encoding the linkers to link proteins.
[0112] Peptide linkers that have some degree of flexibility can be used. The peptide linker can have virtually any amino acid sequence, keeping in mind that suitable peptide linkers generally have sequences that result in flexible peptides. The use of small amino acids such as glycine and alanine is useful for creating flexible peptides. The creation of such sequences is routine for those skilled in the art.
[0113] Suitable linkers can be readily selected and can have any of a variety of suitable lengths, such as from 1 amino acid (e.g., Gly) to 20 amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to 12 amino acids (e.g., from 4 amino acids to 10 amino acids, from 5 amino acids to 9 amino acids, from 6 amino acids to 8 amino acids, or from 7 amino acids to 8 amino acids), and can be 1, 2, 3, 4, 5, 6, or 7 amino acids.
[0114] An example of a flexible linker is a glycine polymer (G) n , glycine-serine polymers (e.g., (GS) n , (GSGGS) n (SEQ ID NO: 40), and (GGGS) n (SEQ ID NO:41), where n is an integer of at least 1), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers can be used, where Gly and Ser are relatively amorphous and can act as neutral tethers between components. Glycine polymers can be used, where glycine has significantly more access to phi-psi space than the equivalent alanine and is much less restricted than residues with long side chains. Examples of spacers include, but are not limited to, The amino acid sequences may include, for example, TIFF2024155943000033.tif12144.
[0115] H. Co-stimulation area Non-limiting examples of suitable costimulatory regions include, but are not limited to, polypeptides derived from 4-lBB (CD137), CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.
[0116] A costimulatory region may have a length of at least, at most, or exactly 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, or 300 amino acids, or any range derivable therein. In some embodiments, the costimulatory region is derived from the intracellular portion of the transmembrane protein 4-1BB (also known as TNFRSF9, CD137, 4-1BB, CDwl37, ILA, etc.). For example, a suitable costimulatory region is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000034.tif4146.
[0117] In some embodiments, the costimulatory region is derived from the intracellular portion of the transmembrane protein CD28 (also known as Tp44). For example, a suitable costimulatory region is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000035.tif4155.
[0118] In some embodiments, the costimulatory region is derived from the intracellular portion of the transmembrane protein ICOS (also known as AILIM, CD278, and CVID1). For example, a suitable costimulatory region is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000036.tif5133.
[0119] In some embodiments, the costimulatory region is derived from the intracellular portion of the transmembrane protein OX-40 (also known as TNFRSF4, RP5-902P8.3, ACT35, CD134, OX40, TXGP1L). For example, a suitable costimulatory region is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000037.tif4131.
[0120] In some embodiments, the costimulatory region is derived from the intracellular portion of the transmembrane protein BTLA (also known as BTLA1 and CD272). For example, a suitable costimulatory region is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000038.tif19158.
[0121] In some embodiments, the costimulatory region is derived from the intracellular portion of the transmembrane protein CD27 (also known as S152, T14, TNFRSF7, and Tp55). For example, a suitable costimulatory region is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000039.tif12160.
[0122] In some embodiments, the costimulatory region is derived from the intracellular portion of the transmembrane protein CD30 (also known as TNFRSF8, D1S166E, and Ki-1). For example, a suitable costimulatory region is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000040.tif26159.
[0123] In some embodiments, the costimulatory region is derived from the intracellular portion of the transmembrane protein GITR (also known as TNFRSF18, RP5-902P8.2, AITR, CD357, and GITR-D). For example, a suitable costimulatory region is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000041.tif12151.
[0124] In some embodiments, the costimulatory region is derived from the intracellular portion of the transmembrane protein HVEM (also known as TNFRSF14, RP3-395M20.6, ATAR, CD270, HVEA, HVEM, LIGHTR, and TR2). For example, a suitable costimulatory region is It may comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity to TIFF2024155943000042.tif12159.
[0125] I. Additional Modifications The polypeptides of the present disclosure may be further chemically modified. The glycosylation of the polypeptide may be altered, for example, by modifying one or more glycosylation sites within the polypeptide sequence to improve the affinity of the polypeptide for an antigen (U.S. Patent Nos. 5,714,350 and 6,350,861).
[0126] The polypeptides of the invention can be pegylated to increase biological half-life by reacting the polypeptide with polyethylene glycol (PEG) or with a reactive ester or aldehyde derivative of PEG under conditions in which one or more PEG groups become attached to the polypeptide. PEGylation of the polypeptide can be carried out by an acylation reaction or an alkylation reaction with a reactive PEG molecule (or an analogous reactive water-soluble polymer). As used herein, the term "polyethylene glycol" is intended to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono (C1-C10) alkoxypolyethylene glycol or aryloxypolyethylene glycol, or polyethylene glycol maleimide. Methods for pegylation of proteins are known in the art and can be applied to the polypeptides of the invention (EP 0154316 and EP 0401384).
[0127] Additionally, the polypeptides can be chemically modified by conjugating or fusing them to serum proteins such as human serum albumin to increase the half-life of the resulting molecule. Such approaches are described, for example, in EP 0322094 and EP 0486525.
[0128] The polypeptides of the present disclosure can be conjugated to diagnostic or therapeutic agents and used diagnostically, for example, to monitor the onset or progression of a disease and to determine the effectiveness of a given treatment regimen. The polypeptides can also be conjugated to therapeutic agents to provide therapy in conjunction with the immunostimulatory effects of the polypeptide. Examples of diagnostic agents include enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, various positron-emitting metals for positron emission tomography, and non-radioactive paramagnetic metal ions. The detectable substances can be linked or conjugated to the polypeptides directly or indirectly via linkers using techniques known in the art. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase. Examples of suitable prosthetic group complexes include streptavidin / biotin and avidin / biotin. Examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, or phycoerythrin. Examples of luminescent materials include luminol. Examples of bioluminescent materials include luciferase, luciferin, and aequorin. Examples of suitable radioactive materials include: 125 I, 131I, Indium 111, Lutetium 171, Bismuth 212, Bismuth 213, Astatine 211, Copper 62, Copper 64, Copper 67, Yttrium 90, Iodine 125, Iodine 131, Phosphorus 32, Phosphorus 33, Scandium 47, Silver 111, Gallium 67, Praseodymium 142, Samarium 153, Terbium 161, Dysprosium 166, Holmium 166, These include rhenium-186, rhenium-188, rhenium-189, lead-212, radium-223, actinium-225, iron-59, selenium-75, arsenic-77, strontium-89, molybdenum-99, rhodium-1105, palladium-109, praseodymium-143, promethium-149, erbium-169, iridium-194, gold-198, gold-199, and lead-211. Chelators can be attached via amines (Meares et al., 1984 Anal. Biochem. 142:68-78), sulfhydral groups of amino acid residues (Koyama 1994 Chem. Abstr. 120:217262t), and carbohydrate groups (Rodwell et al. 1986 PNAS USA 83:2632-2636; Quadri et al. 1993 Nucl. Med. Biol. 20:559-570).
[0129] The polypeptides can also be conjugated to therapeutic agents to provide therapy in combination with the immunostimulatory effects of the polypeptide.
[0130] Further suitable conjugate molecules include ribonucleases (RNases), DNase I, antisense nucleic acids, inhibitory RNA molecules (such as siRNA molecules), immunostimulatory nucleic acids, aptamers, ribozymes, triplex forming molecules, and external guide sequences. Aptamers are small nucleic acids ranging from 15-50 bases in length that fold into defined secondary and tertiary structures (such as stem-loops or G-quartets) and can bind small molecules such as ATP (US Pat. No. 5,631,146) and theophiline (US Pat. No. 5,580,737) as well as larger molecules such as reverse transcriptase (US Pat. No. 5,786,462) and thrombin (US Pat. No. 5,543,293). Ribozymes are nucleic acid molecules that can catalyze chemical reactions intramolecularly or intermolecularly. Ribozymes typically cleave nucleic acid substrates by recognition and binding to the target substrate, resulting in cleavage. The triplex-forming functional nucleic acid molecule can interact with double-stranded or single-stranded nucleic acid by forming a triplex, in which the three strands of DNA form a complex based on Watson-Crick and Hoogsteen pairing. The triplex molecule can bind to the target region with high affinity and specificity.
[0131] Functional nucleic acid molecules can act as effectors, inhibitors, regulators, and stimulators of a specific activity possessed by a target molecule, or can possess novel activities independent of any other molecule.
[0132] J. Cancer-specific Chimeric Antigen Receptors In some embodiments, the cell may further comprise a cancer-specific chimeric antigen receptor (CAR). The term "cancer-specific" in the context of a CAR refers to a CAR that has antigen-binding specificity for a cancer-specific molecule, such as a cancer-specific antigen. In some embodiments, the cancer-specific CAR is in a cell that has a TGF-β CAR. In some embodiments, the cancer-specific CAR and the TGF-β CAR are on separate polypeptides. In some embodiments, the CAR is a bispecific CAR that has antigen binding for a cancer-specific molecule and TGF-β. For example, a bispecific CAR may have a signaling peptide, a cancer molecule-specific scFv, optionally a peptide linker / spacer, followed by a TGF-β scFv, followed by a spacer, a transmembrane domain, and a costimulatory domain. In some embodiments, the bispecific CAR includes one or more additional peptide segments as described herein.
[0133] In some embodiments, a polypeptide of the present disclosure may comprise a CD20 scFv. An example of a CD20 scFv includes the following sequence: TIFF2024155943000043.tif34159
[0134] In some embodiments, a polypeptide of the present disclosure may comprise a CD19 scFv. An example of a CD19 scFv includes the following sequence: TIFF2024155943000044.tif34159
[0135] Other cancer-specific molecules (in addition to CD19 and CD20) may include CAIX, CD33, CD44v7 / 8, CEA, EGP-2, EGP-40, erb-B2, erb-B3, erb-B4, FBP, fetal acetylcholine receptor, GD2, GD3, Her2 / neu, IL-13R-a2, KDR, k-light chain, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, MUC1, NKG2D ligand, carcinoembryonic antigen (h5T4), PSCA, PSMA, TAA targeted by mAb IgE, TAG-72, and VEGF-R2. In some embodiments, the cancer-specific molecule comprises Her2.
[0136] III. Cells Certain embodiments relate to cells comprising the polypeptides or nucleic acids of the present disclosure. In some embodiments, the cells are immune cells or T cells. "T cells" include T helper cells (CD4 + cells), cytotoxic T cells (CD8 + "Cytotoxic cells" include all types of immune cells that express CD3, including CD8 + These cells include T cells, natural killer (NK) cells, and neutrophils, and are capable of mediating cytotoxic responses.
[0137] Suitable mammalian cells include primary cells and immortalized cell lines. Suitable mammalian cell lines include human cell lines, non-human primate cell lines, and murine (e.g., mouse, rat) cell lines, etc. Suitable mammalian cell lines include, but are not limited to, HeLa cells (e.g., American Type Culture Collection (ATCC) No. CCL-2), CHO cells (e.g., ATCC Nos. CRL9618, CCL61, CRL9096), human embryonic kidney (HEK) 293 cells (e.g., ATCC No. CRL-1573), Vero cells, NIH3T3 cells (e.g., ATCC No. CRL-1658), Huh-7 cells, BHK cells (e.g., ATCC No. CCL10), PC12 cells (ATCC No. CRL1721), COS cells, COS-7 cells (ATCC No. CRL1651), RATI cells, mouse L cells (ATCC No. CCLI.3), HLHepG2 cells, Hut-78, Jurkat, HL-60, NK cell lines (e.g., NKL, NK92, and YTS), and the like.
[0138] In some cases, the cells are not immortalized cell lines, but instead are cells (e.g., primary cells) obtained from an individual. For example, in some cases, the cells are immune cells obtained from an individual. In one example, the cells are T lymphocytes obtained from an individual. In another example, the cells are cytotoxic cells obtained from an individual. In yet another example, the cells are stem or progenitor cells obtained from an individual.
[0139] IV. Method Aspects of the present disclosure relate to methods of stimulating immune response. Immune response stimulation can be performed in vitro, in vivo, or ex vivo. In some embodiments, the method relates to a cell that can stimulate immune response in the presence of TGF-β. The method typically involves genetically modifying a mammalian cell with an expression vector or RNA (e.g., in vitro transcribed RNA) that comprises a nucleotide sequence encoding a polypeptide of the present disclosure, or directly transferring the polypeptide into the cell. The cell can be an immune cell (e.g., T lymphocyte or NK cell), stem cell, progenitor cell, etc. In some embodiments, the cell is a cell described herein.
[0140] In some embodiments, genetic modification is performed ex vivo. For example, T lymphocytes, stem cells, or NK cells (or cells described herein) are obtained from an individual, and the cells obtained from the individual are genetically modified to express the polypeptide of the present disclosure. In some cases, the genetically modified cells are activated ex vivo (i.e., TGF-β is contacted with the cells ex vivo). In other cases, the genetically modified cells are introduced into an individual (e.g., the individual from which the cells were obtained), and the genetically modified cells are activated in vivo (i.e., by endogenously produced TGF-β).
[0141] In some embodiments, the method further comprises administration of an additional therapeutic agent, such as a bispecific T cell engager (BITE). Such a therapeutic agent may be administered to the patient in peptide form or expressed in a cell of the present disclosure, such as a cell comprising a TGF-β CAR. The BITE may have antigen specificity for a cancer antigen / cancer molecule known in the art and / or described herein, and may also have antigen specificity for a T cell molecule, such as CD3.
[0142] In some embodiments, the methods relate to administration of the cells or peptides described herein to treat or administer to a person with cancer. In some embodiments, the cancer is adrenal gland cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain / CNS tumors in children or adults, breast cancer, cervical cancer, colon / rectal cancer, endometrial cancer, esophageal cancer, Ewing's family of tumors, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors (GIST), gestational trophoblastic disease, Hodgkin's disease, Kaposi's sarcoma, kidney cancer, pharyngeal and hypopharyngeal cancer, leukemia, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, The cancer is selected from the group consisting of lung cancer, pulmonary carcinoid tumor, lymphoma, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, oral or oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, sarcoma, basal skin cancer, squamous cell skin cancer, melanoma, Merkel cell skin cancer, small intestine cancer, gastric cancer, testicular cancer, thymic cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, and Wilms' tumor.
[0143] Embodiments may be used to treat or ameliorate many immune-mediated, inflammatory, or autoimmune inflammatory diseases, such as hypersensitivity, asthma, diabetes (e.g., type 1 diabetes), transplant rejection, and the like. Examples of such diseases or disorders include, but are not limited to, arthritis (rheumatoid arthritis, e.g., acute arthritis, chronic rheumatoid arthritis, gout or gouty arthritis, acute gouty arthritis, acute immune-mediated arthritis, chronic inflammatory arthritis, osteoarthritis, collagen II-induced arthritis, infectious arthritis, Lyme arthritis, proliferative arthritis, psoriatic arthritis, Still's disease, spondyloarthritis, and juvenile-onset systemic rheumatoid arthritis, osteoarthritis, progressive chronic arthritis (arthritis chronica progrediente), osteoarthritis, primary chronic polyarthritis (polyarthritis chronica), and the like.primaria), reactive arthritis, and ankylosing spondylitis), inflammatory hyperproliferative skin diseases, psoriasis (e.g., plaque psoriasis, guttate psoriasis, pustular psoriasis, and nail psoriasis), atopy (e.g., atopic diseases such as hay fever and Job's syndrome), dermatitis (e.g., contact dermatitis, chronic contact dermatitis, exfoliative dermatitis, allergic dermatitis, allergic contact dermatitis, dermatitis herpetiformis, nummular dermatitis, seborrheic dermatitis, nonspecific dermatitis, idiopathic dermatitis, psoriasis of the skin ... inflammatory disease, chronic idiopathic urticaria, including chronic allergic urticaria and chronic autoimmune urticaria, myositis, polymyositis / dermatomyositis, juvenile dermatomyositis, toxic epidermal necrolysis, scleroderma (including systemic sclerosis), sclerosis (e.g., systemic sclerosis, multiple sclerosis (MS) (spino-optical), MS, primary progressive MS (PPMS), and relapsing-remitting MS (RRMS)), progressive systemic sclerosis, atherosclerosis, arteriosclerosis, disseminated sclerosis, ataxic sclerosis), neuromyelitis optica (NMO), inflammation infectious bowel diseases (IBD) (e.g., Crohn's disease, autoimmune-mediated gastrointestinal diseases, colitis (ulcerative colitis, ulcerative colitis, microscopic colitis, collagenous colitis, polypoidal colitis, necrotizing enterocolitis, and full-thickness colon) inflammatory bowel disease), enteritis, pyoderma gangrenosum, erythema nodosum, primary sclerosing cholangitis, respiratory distress syndrome (e.g., adult or acute respiratory distress syndrome (ARDS)), meningitis, inflammation of the whole or part of the uvea, iritis, choroiditis, autoimmune blood disorders, rheumatoid spondylitis, rheumatoid synovitis, hereditary angioedema, cranial nerve damage in cases such as meningitis, herpes gestationis, pemphigoid of gestationis, pruritisscroti), autoimmune premature ovarian failure, sudden deafness due to autoimmune conditions, IgE-mediated diseases (e.g., anaphylaxis and allergic and atopic rhinitis), encephalitis (e.g., Rasmussen's encephalitis and limbic and / or brain stem encephalitis), uveitis (e.g., anterior uveitis, acute anterior uveitis, granulomatous uveitis, nongranulomatous uveitis, phacoantigenic uveitis, posterior uveitis, or autoimmune uveitis), glomerulonephritis (GN) with or without nephrotic syndrome (e.g., primary GN, immune-mediated GN, membranous GN (membranous nephropathy), idiopathic membranous GN or idiopathic membranous nephropathy, type I and chronic or acute glomerulonephritis including membranous or membranoproliferative GN (MPGN), including type II, and rapidly progressive GN), proliferative nephritis, autoimmune polyendocrine deficiencies, balanitis (e.g., plasma cell localized balanitis), balanoposthitis, erythema annulare centrifugally, erythema dyschromicus perstans, erythema multiforme, granuloma annulare, lichen sclerosus atrophicus, lichen simplex chronicus, lichen spinous, lichen planus, ichthyosis phyllodes, epidermolytic hyperkeratosis, precancerous keratosis, pyoderma gangrenosum, allergic conditions and responses, allergic reactions, eczema (e.g., allergic or atopic eczema, asteatotic eczema, dyshidrotic eczema, and bullous palmoplantar eczema), asthma (e.g., asthma bronchiale, bronchial asthma,and autoimmune asthma), conditions with T cell infiltration and chronic inflammatory responses, immune responses to foreign antigens such as fetal ABO blood groups during pregnancy, chronic pulmonary inflammatory diseases, autoimmune myocarditis, leukocyte adhesion deficiency, lupus (e.g., lupus nephritis, lupus encephalitis, pediatric lupus, non-renal lupus, extrarenal lupus, discoid lupus and discoid lupus erythematosus, alopecia lupus, systemic lupus erythematosus (SLE) such as cutaneous SLE or subacute cutaneous SLE, neonatal lupus syndrome (NLE), and disseminated lupus erythematosus), juvenile-onset (Type I) diabetes (e.g., childhood insulin-dependent diabetes mellitus (IDDM)) and adult-onset diabetes (Type II diabetes), and autoimmune diabetes. Further considerations include immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T lymphocytes, sarcoidosis, granulomatous diseases (e.g., lymphomatoid granulomatosis, Wegener's granulomatosis), agranulocytosis, vasculitis (e.g., vasculitis, large vessel vasculitis (including polymyalgia rheumatica and giant cell (Takayasu) arteritis), medium vessel vasculitis (including Kawasaki disease and polyarteritis nodosa / periarteritis nodosa), microscopic polyarteritis, immune vasculitis, CNS vasculitis, cutaneous vasculitis, hypersensitivity vasculitis, necrotizing vasculitis (e.g., systemic necrotizing vasculitis), and ANCA-associated vasculitis (e.g., Churg-Strauss vasculitis or syndrome (CSS) and ANCA-associated small vessel vasculitis), temporal arteritis, aplastic anemia, autoimmune aplastic anemia, Coombs positive anemia, diesease anemia, vasculitis ... Almond-Blackfan anemia, hemolytic anemia or immune-mediated hemolytic anemia (e.g., autoimmune hemolytic anemia (AIHA)), Addison's disease, autoimmune neutropenia, pancytopenia, leukopenia, diseases with leukocyte leakage, CNS inflammatory disorders, Alzheimer's disease, Parkinson's disease, multiple organ injury syndromes (e.g., secondary to sepsis, trauma, or hemorrhage), antigen-antibody complex-mediated diseases, antiglomerular basement membrane disease, antiphospholipid syndrome, allergic neuritis, Behcet's disease / syndrome, Castleman syndrome, Goodpasture's syndrome, Raynaud's syndrome, Sjogren's syndrome, Stevens-Johnson syndrome, pemphigoid (e.g., bullous pemphigoid and cutaneous pemphigoid), pemphigus (pemphigus vulgaris, pemphigus foliaceus, pemphigus mucus-membrane pemphigoid)pemphigoid, and pemphigus erythematosus), autoimmune polyendocrinopathy, Reiter's disease or syndrome, burns, preeclampsia, immune complex disorders (e.g., immune complex nephritis), antibody-mediated nephritis, polyneuropathy, chronic neuropathy (e.g., IgM polyneuropathy or IgM-mediated neuropathy), autoimmune or immune-mediated thrombocytopenia (e.g., idiopathic thrombocytopenic purpura (ITP) including chronic or acute ITP), scleritis (e.g., idiopathic keratoscleritis, episcleritis), autoimmune diseases of the testes and ovaries (e.g., autoimmune orchitis and oophoritis), primary hypothyroidism, hypoparathyroidism, autoimmune endocrine disorders (e.g., autoimmune thyroiditis, Hashimoto's disease, chronic thyroiditis (Hashimoto's thyroiditis), thyroiditis, such as acute or subacute thyroiditis), autoimmune thyroid disease, idiopathic hypothyroidism, Graves' disease, polyglandular syndromes (e.g., autoimmune polyglandular syndromes (or polyendocrinopathy syndromes)), paraneoplastic syndromes (e.g., neurological paraneoplastic syndromes, such as Lambert-Eaton myasthenic syndrome or Eaton-Lambert syndrome, stiff-man or stiff-person syndrome), encephalomyelitis (e.g., allergic encephalomyelitis or encephalomyelitis allergy, and experimental allergic encephalomyelitis (EAE), experimental autoimmune encephalomyelitis), myasthenia gravis (e.g., , thymoma-associated myasthenia gravis), cerebellar degeneration, neuromyotonia, opsoclonus or opsoclonus-myoclonus syndrome (OMS), as well as sensory neuropathy, multifocal motor neuropathy, Sheehan syndrome, autoimmune hepatitis, chronic hepatitis, lupoid hepatitis, giant cell hepatitis, chronic active hepatitis or autoimmune chronic active hepatitis, lymphocytic interstitial pneumonia (LIP), bronchiolitis obliterans (non-transplant) vs. NSIP, Guillain-Barre syndrome, Berger's disease (IgA nephropathy), idiopathic IgA nephropathy, linear IgA dermatosis, acute febrile neutrophilic dermatosis, subcorneal pustular dermatosis, transient acanthosis nigricans Melting derma, cirrhosis (e.g., primary biliary cirrhosis and pulmonary cirrhosis), autoimmune enteropathy syndromes, Celiac or Coeliac disease, Celiac sprue (gluten enteropathy), refractory sprue, idiopathic sprue, cryoglobulinemia, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), coronary artery disease, autoimmune ear disease (e.g., autoimmune inner ear disease (AIED), autoimmune hearing loss), polychondritis (e.g., refractory or relapsing or relapsing polychondritis), pulmonary alveolar proteinosis, Cogan's syndrome / nonsyphilitic interstitial keratitis, Bell's palsy, Sweet's disease / syndrome, autoimmune rosacea, shingles-associated pain, amyloidosis, non-cancerous lymphocytosis, primary lymphocytosis including monoclonal B-cell lymphocytosis (e.g., benign monoclonal gammopathy and monoclonal gammopathy of undetermined significance (MGUS)), peripheral neuropathy, paraneoplastic syndromes, channelopathies (e.g., epilepsy, migraine, arrhythmias, myopathy, hearing loss, vision loss, periodic paralysis, and channelopathies of the CNS), autism, inflammatory myopathies, focal or segmental or focal segmental glomerulosclerosis (FSGS),Endocrine eye disorders, uveoretinitis, chorioretinitis, autoimmune hepatopathy, fibromyalgia, polyendocrine deficiency, Schmidt syndrome, adrenalitis, gastrotrophy, presenile dementia, demyelinating diseases (e.g., autoimmune demyelinating diseases and chronic inflammatory demyelinating polyneuropathy), Dressler syndrome, alopecia areata, alopecia totalis, CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia), male and female autoimmune infertility (e.g., due to antisperm antibodies), mixed connective tissue disease, Chagas disease, rheumatic fever, recurrent abortions, farmer's lung, erythema multiforme, cardiotomy Postoperative syndrome, Cushing's syndrome, Bird breeder's disease, Allergic granulomatous vasculitis, Benign lymphocytic vasculitis, Alport syndrome, Alveolitis (e.g. allergic alveolitis and fibrosing alveolitis), Interstitial lung disease, Transfusion reactions, Leprosy, Malaria, Parasitic diseases (e.g. leishmaniasis, trypanosomiasis, schistosomiasis, ascariasis, aspergillosis), Samter's syndrome, Kaplan's syndrome, Dengue fever, Endocarditis, Endomyocardial fibrosis, Diffuse interstitial pulmonary fibrosis, Interstitial pulmonary fibrosis, Pulmonary fibrosis, Idiopathic pulmonary fibrosis, Cystic fibrosis, Endophthalmitis, Erythema elevatum, Erythroblastosis fetalis, Eosinophils fasciitis, Schulman syndrome, Felty syndrome, filariasis, cyclitis (e.g., chronic cyclitis, metachronous cyclitis, iridocyclitis (acute or chronic), or Fuchs' cyclitis), Henoch-Schönlein purpura, human immunodeficiency virus (HIV) infection, SCID, acquired immune deficiency syndrome (AIDS), echovirus infection, sepsis, endotoxemia, pancreatitis, thyrotoxicosis, parvovirus infection, rubella virus infection, post-vaccination syndrome, congenital rubella infection, Epstein-Barr virus infection, mumps, Evans syndrome, autoimmune Hypogonadism, Sydenham's chorea, poststreptococcal nephritis, thromboangiitis obliterans, thyrotoxicosis, tabes dorsalis, choroiditis, giant cell polymyalgia, chronic hypersensitivity pneumonitis, keratoconjunctivitis sicca, epidemic keratoconjunctivitis, idiopathic nephritic syndrome, microlesion disease, benign familial and ischemia-reperfusion injury, transplanted organ reperfusion, retinal autoimmunity, arthritis, bronchitis, chronic obstructive airway / lung disease, silicosis, aphthous stomatitis, arteriosclerotic disorders, asperniogenese, autoimmune hemolysis, Beck's disease, cryoglobulinemia, Dupuytren's contracture, phacosensitivity endophthalmitis, allergic enterocolitis,Erythema nodosum leprosum, idiopathic facial palsy, chronic fatigue syndrome, rheumatic fever, Hamman-Rich disease, sensorineural deafness, paroxysmal hemoglobinuria, hypogonadism, focal ileitis, leukopenia, infectious mononucleosis, transverse myelitis, primary idiopathic myxedema, nephrosis, sympathetic ophthalmia, granulomatous orchitis, pancreatitis, acute polyradiculitis, pyoderma gangrenosum, Kervan thyroiditis, acquired splenic atrophy, nonmalignant thymoma, leukoplakia, toxic shock syndrome, food poisoning, conditions with T cell infiltration, leukocyte adhesion deficiency, immune disorders related to acute and delayed hypersensitivity mediated by cytokines and T lymphocytes Response, diseases with leukocyte leakage, multiorgan injury syndrome, antigen-antibody complex-mediated disease, antiglomerular basement membrane disease, allergic neuritis, autoimmune polyendocrinopathy, oophoritis, primary myxedema, autoimmune atrophic gastritis, sympathetic ophthalmia, rheumatic diseases, mixed connective tissue disease, nephrotic syndrome, insulitis, polyendocrine deficiency, autoimmune polyglandular syndrome type I, adult-onset idiopathic hypoparathyroidism (AOIH), cardiomyopathies (e.g., dilated cardiomyopathy), epidermolysis bullosa acquisita (EBA), hemochromatosis, myocarditis, nephrotic syndrome, primary sclerosing cholangitis, suppurative or nonsuppurative sinusitis , acute or chronic sinusitis, ethmoid sinusitis, frontal sinusitis, maxillary sinusitis or sphenoid sinusitis, eosinophil-related disorders (e.g., eosinophilia, pulmonary infiltrative eosinophilia, eosinophilic myalgia syndrome, Löffler syndrome, chronic eosinophilic pneumonia, tropical pulmonary eosinophilia), bronchopneumonia, aspergillosis, aspergilloma, or eosinophil-containing granulomas, anaphylaxis, seronegative spondyloarthritis, polyendocrine autoimmune diseases, sclerosing cholangitis, scleral, episcleral, chronic mucocutaneous candidiasis, Bruton's syndrome, transient hypogammaglobulinemia of infancy, Wiskott-Aldrich syndrome, telangiectasia ataxia syndrome, vascular ectasia, autoimmune disorders associated with collagen diseases, rheumatism, nervous system diseases, lymphadenitis, decreased blood pressure response, vascular insufficiency, tissue damage, cardiovascular ischemia, hyperalgesia, renal ischemia, cerebral ischemia, and diseases involving angiogenesis, allergic hypersensitivity disorders, glomerulonephritis, reperfusion injury, ischemic reperfusion injury, reperfusion injury of the myocardium or other tissues, lymphomatous tracheobronchitis, inflammatory skin diseases, skin diseases with an acute inflammatory component, multiple organ failure, bullous diseases, renal cortical necrosis, acute purulent meningitis or other central nervous system inflammatory disorders, ocular and orbital inflammatory disorders, granulocyte transfusion associated syndrome,These include cytokine-induced toxicity, narcolepsy, acute severe inflammation, chronic intractable inflammation, pyelitis, intra-arterial hyperplasia, peptic ulcers, valvular inflammation, graft-versus-host disease, contact hypersensitivity, asthmatic airway hyperresponsiveness, and endometriosis.
[0144] V. Pharmaceutical Compositions The present disclosure includes methods for modulating an immune response in a subject in need thereof. The present disclosure includes cells, which may be in the form of a pharmaceutical composition that can be used to induce or modify an immune response.
[0145] Compositions according to the present disclosure are generally administered via any common route, including but not limited to parenteral, orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, or intravenous injection.
[0146] The compositions of the invention are typically administered using a method compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunomodulating. The amount to be administered will depend on the subject being treated. Precise amounts of active ingredient required to be administered depend on the practitioner's judgment.
[0147] The method of application can vary widely. Any of the conventional methods of administering a pharmaceutical composition containing cellular components can be applied. The dosage of the pharmaceutical composition depends on the route of administration and will vary depending on the size and health of the subject.
[0148] In many instances, it may be desirable to administer multiple doses, at least about 3, 4, 5, 6, 7, 8, 9, 10, or more. Administration may be at intervals of 2 days to 12 weeks, more typically 1 to 2 weeks. Administration may be followed by assays for alloreactive immune responses and T cell activity.
[0149] The phrase "pharmacologically acceptable" or "pharmacologically acceptable" refers to molecular entities and compositions that do not produce adverse, allergic or other adverse reactions when administered to animals or humans. As used herein, "pharmacologically acceptable carriers" include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, as well as isotonic and absorption delaying agents, and the like. The use of such media and agents for pharma- ceutical active substances is well known in the art. Except where any commonly used media or agent is incompatible with the active ingredient, its use in immunogenic and therapeutic compositions is contemplated. The pharmaceutical compositions of the present disclosure are pharma- ceutical acceptable compositions.
[0150] The compositions of the present disclosure may be formulated for parenteral administration, for example, formulated for injection via intravenous, intramuscular, subcutaneous, or intraperitoneal routes. Such compositions can typically be prepared as injectables, i.e., as liquid solutions or suspensions, or solid forms suitable for preparing solutions or suspensions when liquid is added prior to injection, or the preparations can be emulsified.
[0151] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and formulations including sesame oil, peanut oil, or aqueous propylene glycol, and should be stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi.
[0152] Sterile injectable solutions are prepared by mixing the required amount of the active ingredient (i.e., the cells of the present disclosure) in the appropriate solvent along with various other ingredients enumerated above, as required, followed by filtered sterilization. Dispersions are prepared by mixing the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
[0153] The effective amount of the composition is determined based on the intended goal. The term "unit dose" or "dosage" refers to a physically discrete unit suitable for use in a subject, each unit containing a predetermined amount of the composition, which is calculated to obtain the desired response as discussed herein in conjunction with administration (i.e., the appropriate route and regimen). The amount administered depends on the desired outcome and / or protection, depending on the number of therapeutic agents and the unit dose. The exact amount of the composition also depends on the physician's judgment and is specific to each individual. Factors that affect the dosage include the subject's physical and clinical condition, the route of administration, the intended therapeutic goal (relief of symptoms versus cure), and the efficacy, stability, and toxicity of the particular composition. Once formulated, the solution is administered in a manner compatible with the dosage formulation and in such amount as is therapeutically or prophylactically effective. The formulations are easily administered in a variety of dosage forms, such as the injectable solution types described above.
[0154] VI. Arrays The antigen-binding domain of the present disclosure includes the following VH (variable heavy chain) and VL (variable light chain) regions: TIFF2024155943000045.tif174160
[0155] The corresponding CDRs of the VH and VL regions of scFv#1 have the following amino acid sequences: TIFF2024155943000046.tif26160.
[0156] The corresponding CDRs of the VH and VL regions of scFv#2 have the following amino acid sequences: TIFF2024155943000047.tif26160.
[0157] The corresponding CDRs of the VH and VL regions of scFv#3 have the following amino acid sequences: TIFF2024155943000048.tif26160.
[0158] Detection peptides of the present disclosure include, for example: TIFF2024155943000049.tif19160 may be included.
[0159] Exemplary signal peptides include: TIFF2024155943000050.tif5128. Other exemplary signal peptides include: Contains TIFF2024155943000051.tif12128.
[0160] Exemplary peptide spacer hinge regions include: Contains TIFF2024155943000052.tif64160.
[0161] Exemplary peptide linkers include, for example, Contains TIFF2024155943000053.tif26163.
[0162] Exemplary transmembrane domains include: TIFF2024155943000054.tif4128, CD8 beta derived TIFF2024155943000055.tif4128, CD4-derived TIFF2024155943000056.tif4128, derived from CD3 Zeta TIFF2024155943000057.tif5128, CD28 derived TIFF2024155943000058.tif4128, CD134(OX40) derived TIFF2024155943000059.tif4128, and CD7-derived Contains TIFF2024155943000060.tif4128.
[0163] Exemplary costimulatory regions include: Contains TIFF2024155943000061.tif121160.
[0164] In some embodiments, the endodomain comprises an ITAM motif. The ITAM motif is YX1X2(L / I), where X1 and X2 are independently any amino acid (SEQ ID NO:64). In some cases, the ITAM motif is repeated twice within the endodomain, and the first and second instances of the ITAM motif are separated from each other by 6-8 amino acids, e.g., (YX1X2(L / I))(X3). n (YX1X2(L / I)), where n is an integer from 6 to 8, and each of the 6 to 8 X3 can be any amino acid (SEQ ID NO:65).
[0165] Exemplary endodomains include: TIFF2024155943000062.tif187160TIFF2024155943000063.tif245160TIFF2024155943000064.tif70160, or a polypeptide from thereof. EXAMPLES
[0166] VII. Working Examples The following examples are included to demonstrate embodiments of the present invention. Those skilled in the art should understand that the techniques disclosed in the following examples represent techniques discovered by the inventors that function well in the practice of the present invention, and therefore can be considered to constitute preferred modes of practice. However, in light of this disclosure, those skilled in the art should understand that numerous changes can be made in the specific embodiments disclosed and still obtain the same or similar results without departing from the spirit and scope of the present invention.
[0167] Example 1 This disclosure describes single chain variable fragments (scFv) that neutralize human and mouse TGF-β and chimeric antigen receptors (CARs) that are responsive to human and mouse TGF-β. The level of conservation of TGF-β across mammals suggests that the described scFvs and CARs can be used to bind TGF-β in most mammals. Two scFvs are constructed by linking the heavy chain variable domain (VH) and the light chain variable domain (VL) of an anti-TGF-β antibody using a (G4S)3 linker to give the final order N-terminus-VH-(G4S)3-VL-C-terminus. These scFvs can be produced by transfecting eukaryotic cells with DNA sequences encoding the scFv amino acid sequences shown in the table below. TIFF2024155943000065.tif90163
[0168] Each scFv can be tagged with a leader (i.e., signal) peptide from mouse kappa light chain, so that secreted scFvs can be collected directly from the medium in which the producing cells are cultured. The scFvs can also be tagged at the N-terminus (after the leader peptide but before the VH sequence) with a marker such as the DYKDDDDK (SEQ ID NO:17) epitope, HA tag, or cMyc tag adjacent to a GGS linker. Each scFv is administered directly to neutralize human or mouse TGF-β. scFv#1 and scFv#2 are superior to scFv#3 (Figures 1 and 7). Furthermore, each scFv can be used to construct a TGF-β-responsive CAR. The CAR is a fusion protein composed of an extracellular antigen-binding domain, an extracellular spacer, a transmembrane domain, a costimulatory signaling region (the number of which varies depending on the specific CAR design), and a CD3 zeta signaling domain / endodomain. TGF-β CARs can be constructed using the above-mentioned scFvs as extracellular antigen-binding domains. Immune cells, including T cells and natural killer (NK) cells, can be engineered to express TGF-β CARs by various methods, such as viral transduction, DNA nucleofection, and RNA nucleofection. TGF-β bound to TGF-β CARs can activate human T cells, thereby changing TGF-β signaling from an immunosuppressive response to an immunostimulatory response. TGF-β CARs can also be used as co-receptors to counteract immunosuppression and enhance T cell-mediated responses in any adoptive T cell therapy, whether based on tumor-infiltrating lymphocytes, T cell receptor engineering, or other CARs.
[0169] As shown in Figure 2, TGF-β CAR is efficiently expressed on the surface of primary human T cells. TGF-β CAR was generated using scFv#2. Surface staining and flow cytometry show that TGF-β CAR is expressed on the surface of primary human CD4+ and CD8+ T cells. The extracellular domain of the receptor contains an N-terminal FLAG epitope. EGFRt is a truncated epidermal growth factor receptor, which indicates cell transduction. We further found that TGF-β CAR is more efficiently expressed on the cell surface than dominant-negative TGF-β receptor (Figure 9). Dominant-negative TGF-β receptor (DNR), which contains a truncated TGF-β receptor chain II that does not have the intracellular signaling domain, has been reported to inhibit TGF-β signaling and improve T cell effector function. However, DNR, unlike TGF-β CAR, is not efficiently expressed on the cell surface. The data shown in Figure 9 are from transduction of primary human CD4+ T cells with lentiviruses encoding either FLAG-tagged TGF-β CAR or FLAG-tagged DNR. Each receptor is tagged to a truncated epidermal growth factor receptor (EGFRt) via a T2A cleavage peptide, so that transduced cells can be identified by EGFRt staining, while receptor surface expression can be identified by FLAG staining. The results in Figure 9 show that TGF-β CAR is expressed much more efficiently on the T cell surface than DNR.
[0170] Figure 3 shows that TGF-β CAR blocks endogenous TGF-β signaling. Expression of TGF-β CAR in primary human T cells blocks TGF-β signaling through the SMAD pathway. T cells expressing the indicated receptors were incubated with the indicated concentrations of TGF-β for 30 minutes and probed for phosphorylated SMAD2 by Western blot. EGFRt represents T cells expressing a truncated epidermal growth factor receptor and acts as a "no CAR" control, whereas no scFv represents T cells expressing a CAR that does not have any ligand-binding scFv domain but is otherwise identical to the TGF-β CAR length. The "long" and "short" labels following the TGF-β CARs represent the length of their extracellular peptide spacers. As shown in Figure 6, TGF-β CAR-T cells proliferate in response to TGF-β. TGF-β CAR-expressing T cells convert TGF-β from a growth-inhibiting cytokine to a growth-promoting cytokine.
[0171] Furthermore, we found that TGF-β CARs activate T cells and induce cytokine production (Figure 4). As shown in Figure 4, TGF-β CAR-T cells upregulate the expression of CD69 activation marker and produce the immunostimulatory cytokines IFN-γ and TNF-α in response to TGF-β exposure. After 24 h of incubation with or without TGF-β, CD69 upregulation was monitored by surface staining. After 24 h of incubation with or without TGF-β, cytokine production was detected by applying the protein transport inhibitor brefeldin A and performing intracellular staining. "No scFv" represents CARs without any ligand-binding scFv domain.
[0172] Unlike TGF-β CARs, dominant-negative TGF-β receptors cannot induce cytokine production. Dominant-negative TGF-β receptors have also been reported to inhibit TGF-β signaling, but they do not induce immunostimulatory effects such as the production of TNF-α (Figure 5). "Tβ short" and "Tβ long" are two different types of TGF-β CARs, "Dom-Neg" represents a dominant-negative TGF-β receptor, and "no scFv" represents a CAR without any ligand-binding scFv domain.
[0173] We further found that the function of TGF-β CARs can be tuned by the choice of costimulatory domain. As shown in Figure 10, switching between CD28 and 4-1BB costimulatory domains alters the level of cytokine production in response to TGF-β. Furthermore, we found that TGF-β consistently induced TNF-α production in a dose-dependent manner across cells bearing TGF-β CARs from different donors, suggesting that the performance of the CARs is robust enough to be trusted for clinical application (Figure 11).
[0174] We also found that the spacer length of TGF-β CAR regulated the induction threshold. Increasing the length of the extracellular spacer raised the TGF-β threshold for CAR induction (Figure 12). This suggests that CAR responsiveness to application requirements can be customized by altering the linkage between the ligand-binding domain and the intracellular signaling domain. The "short spacer" contained the hinge portion of human IgG4, and the "long spacer" contained the hinge-CH2-CH3 of IgG4.
[0175] We next found that soluble ligand-mediated CAR dimerization induces CAR signaling. Jurkat cell lines carrying the indicated CARs are shown in Figure 13. Both GFP CAR#1 and GFP CAR#3 exist primarily in homodimeric form, and these two CARs bind different epitopes on EGFP and can bind to individual EGFP molecules simultaneously. GFP CAR#1 and GFP CAR#2 bind the same epitope on EGFP, but CAR#2 exists as a monomer rather than a homodimer. The results reveal that CAR signaling can be promoted by ligand-mediated CAR dimerization, but that the ligand or CAR itself does not need to pre-exist as a dimer (Figure 13). One possible mechanism by which soluble ligands can induce CAR signaling is to form an immune synapse by linking receptors on two different cells. This mechanism is consistent with the observation that Jurkat cells expressing a single GFP CAR can be activated by dimeric but not monomeric EGFP. It is also consistent with the observation that a mixture of two Jurkat cell lines expressing different GFP CARs can be activated by both dimeric and monomeric EGFP. In this example, monomeric EGFP can also induce cell-cell tethering because the CARs in the two Jurkat cell lines bind to two different epitopes on the same EGFP molecule (Figure 14).
[0176] We found that TGF-β CAR can be induced in cell-to-cell contact-dependent and -independent manners. Although cell-to-cell contact is one possible mechanism by which soluble ligands such as EGFP and TGF-β can induce CAR signaling, CAR-T cell activation can be induced by soluble ligands even in the absence of cell-to-cell contact. In Figure 15, Jurkat cells stably expressing TGF-β CAR and an EGFP reporter expressed from the NFAT promoter are plated at various cell densities and incubated in the presence or absence of 5ng / mL TGF-β. Even at extremely low densities where cells exist primarily as isolated single cells, EGFP signal is clearly observed in the presence of TGF-β. Furthermore, no increase in EGFP production with cell density is observed for a 10-fold range of cell densities (500-5000 cells / cm^2) (Figure 15). These results indicate that soluble TGF-β can induce T cell activation independent of cell-to-cell contact. However, EGFP production increased significantly above a threshold cell density, revealing the contribution of cell-cell contact at high cell density levels. To further evaluate this phenomenon, primary human CD4+ T cells expressing TGF-β CAR were labeled with the calcium indicator Fluo-4-AM and imaged by fluorescence microscopy. The Fluo-4-AM signal observed after addition of TGF-β in the absence of cell-cell contact supports that TGF-β CAR-T cells can be activated by soluble ligands without cell-cell junctions (Figure 16).
[0177] TGF-β CARs address the need for immune cells to neutralize the role of TGF-β as an immunosuppressive driver in the tumor microenvironment. Although CAR-T cell therapy has achieved notable clinical results against B-cell malignancies, efficacy against solid tumors is still significantly limited. Solid tumors are known to result in a highly immunosuppressive microenvironment due to the overproduction of TGF-β and other cytokines, which ultimately results in T cell inactivation. TGF-β CARs confer on T cells not only the ability to counteract immunosuppression by reducing signaling through the endogenous TGF-β pathway, but also the ability to specifically induce T cell activation in the presence of TGF-β. T cell activation prompts immune cells to produce and proliferate immunostimulatory cytokines, thereby transforming TGF-β from an immunosuppressive signal into an activating stimulus that activates antitumor immune responses.
[0178] Example 2: Design of polyfunctional regulatory T cell therapy for autoimmune diseases This example describes a method that can be used to engineer regulatory T cells (Tregs) expressing chimeric antigen receptors (CARs), which can be activated by transforming growth factor beta (TGF-β) to selectively expand ex vivo, maintain robust suppressive function in vivo, and secrete anti-interleukin 6 receptor alpha (IL-6Rα) single chain variable fragment (scFv) to effectively reduce inflammation in a mouse model of rheumatoid arthritis (RA). It is contemplated that other autoimmune diseases, such as those known in the art and / or described herein, may also be treated by the methods described in this example and in the present disclosure.
[0179] Adoptive T cell therapy using conventional T cells (Tconvs) expressing chimeric antigen receptors (CARs) has provided remarkable clinical efficacy against refractory cancers, especially B cell malignancies. However, the application of CAR-T cell therapy to treat autoimmune diseases is still in its infancy.
[0180] Tregs suppress the function of Tconv by multiple mechanisms, one of which is the secretion of TGF-β, a potent immunosuppressive cytokine that inhibits both effector T cell and natural killer cell functions. We have developed TGF-β CARs that specifically activate Tconv in the presence of TGF-β (Figure 4), and have confirmed that TGF-β CAR-T cells respond to both soluble and immobilized forms of TGF-β. Human CD4+Tconvs and CD8+Tconvs expressing TGF-β CARs induce robust NFAT signaling and produce Th2 cytokines in the presence of TGF-β, despite the fact that TGF-β is normally a highly immunosuppressive agent (Figure 4).
[0181] TGF-β CAR is considered to be uniquely suitable for Treg therapy for the following reasons: 1) TGF-β is known to promote the differentiation of Tregs, and therefore TGF-β-mediated proliferation of CAR-expressing T cells presents a method to selectively expand Tregs while preventing the proliferation of contaminating Tconvs. We confirmed that TGF-β drives robust proliferation of TGF-β CAR-expressing Tconvs only in the presence of irradiated feeder cells. In the absence of feeder cells, proliferation of TGF-β CAR-Tconvs is specifically inhibited by the presence of TGF-β, and the inhibition is significantly stronger for TGF-β CAR-Tconvs compared to unmodified Tconvs or Tconvs expressing non-TGF-β CARs. Our experimental results suggest that TGF-β present as a natural homodimer can lead to the formation of a bond between two T cells, both of which express TGF-β CARs. This cell-cell junction can result in sibling-killing toxicity between Tconvs. This toxicity can be more than offset by the proliferative response resulting from CAR signaling, but only with the support of irradiated feeder cells. Unlike Tconvs, Tregs do not exhibit granzyme-mediated cytotoxicity and are not suppressed by endogenous TGF-β signaling. Thus, in the absence of feeder cell support, TGF-β CAR-expressing Tregs could be selectively expanded over contaminating Tconvs in TGF-β-driven ex vivo expansion protocols, addressing one of the major obstacles to generating therapeutic Tregs. 2) Activated Tregs naturally produce TGF-β, thus providing a mechanism for sustained activation of TGF-β CAR-Tregs in vitro and in vivo. Antigen-specific Tregs have been shown to be more effective than polyclonal Tregs in immunosuppression. On the other hand, it has also been shown that Tregs, once activated, can exert suppressor functions in an antigen-nonspecific manner. Furthermore, preactivated polyclonal Tregs have been shown to inhibit collagen-induced arthritis in mice.Taken together, these results suggest that antigen-specific Tregs may be more effective because they can be activated more easily than non-antigen-specific Tregs, and that specificity for target cells, although possibly advantageous, is not essential for therapeutic function. Natural antigen-specific Tregs are difficult to isolate and expand to sufficiently large amounts for therapeutic applications. The introduction of transformed T cell receptors (TCRs) offers an attractive alternative, but each disease requires its own specific TCR and the availability of suitable antigen targets, the latter of which has been recognized as the main bottleneck in the development of T cell therapy. Because TGF-β production is a natural product of Tregs independent of TCR specificity, TGF-β CARs present a generalized strategy that allows sustained Treg activation and could support Treg-mediated suppression against a wide range of disease targets without the need for disease-specific receptors.
[0182] This example provides a novel methodology and specific Treg product for cellular immunotherapy against autoimmune diseases, using RA as a disease model for early stage research. The overall aim is to establish a generalized approach to generate therapeutic Tregs with sustained therapeutic function and to demonstrate the utility of engineered Tregs in a collagen-induced arthritis model in mice.
[0183] A. Development of a TGF-β-mediated ex vivo expansion protocol for robust Treg expansion Primary human Tregs can be isolated from healthy donor blood samples using the RosetteSep CD4+ T cell enrichment kit followed by magnetic bead-based enrichment of CD127- and CD25+ cells. Isolated cells can be activated with CD3 / CD28 Dynabeads and cultured for 2 days in complete medium (RPMI + 10% heat-inactivated fetal bovine serum) supplemented with 300U / ml IL-2 prior to lentiviral transduction. A lentiviral vector encoding a TGF-β CAR tagged with truncated epidermal growth factor receptor (EGFRt) (via a T2A cleavage peptide) was previously constructed and validated by transducing primary human Tconvs. CAR-expressing cells can be isolated by magnetic bead-based sorting of EGFRt+ cells. This sorting scheme eliminates the need for direct antibody binding to the CAR, reducing the chance of non-productive T cell activation. Sorted CAR-Tregs can be expanded in 96-well plates under various culture conditions: (a) IL-2 alone at 300 U / ml, (b) TGF-β alone with a concentration gradient (1-20 ng / ml), (c) a gradient of IL-2 (50-300 U / ml) and TGF-β (1-20 ng / ml), (d) a concentration gradient of IL-2 and TGF-β plus irradiated feeder cells (TM-LCL) at a T cell:irradiated feeder cell (TM-LCL) ratio of 1:7. Viable cell numbers can be quantified by flow cytometry over a 3-week period. Additionally, Foxp3 expression levels can be quantified by intracellular staining over the course of the cell preparation process starting with freshly isolated CD4+ / CD25+ / CD127- cells. A "no scFv" CAR, identical to the TGF-β CAR except that it does not have the TGF-β binding scFv domain, can be constructed and included as a negative control.
[0184] Through the studies described in this example, it can be clarified that (1) TGF-β CAR expression can result in Tregs with the ability to specifically proliferate in response to the addition of TGF-β, and (2) the optimal combination of IL-2, TGF-β, and / or feeder cells for high efficiency (defined by high fold expansion) and high purity (defined by the presence of minimal contaminating Tconv) ex vivo Treg expansion. The inventors developed multiple TGF-β CARs with different structural characteristics and observed the individual signaling thresholds of these CARs in response to TGF-β. Two different TGF-β CARs, one with a short (12 amino acids) extracellular spacer and the other with a long (229 amino acids) extracellular spacer, can be evaluated to identify the optimal construct for Treg applications.
[0185] B. Optimization of TGF-β CAR-Treg suppressor function in vitro and in vivo The suppressor function of Tregs stably expressing TGF-β CARs can be further investigated. Tregs are isolated, transduced, and sorted as described above. Both long and short spacer TGF-β CARs can be evaluated. As a negative control, a portion of CD4+ T cells (before enrichment for CD127- / CD25+ phenotype) can be transduced and sorted to provide a comparison of TGF-β CAR-Tconv to engineered Tregs. As a second negative control, Tregs transduced with the scFv-less CAR described above can be included in the study. Sorted CAR-Tregs can be expanded in complete medium supplemented with 300 U / ml IL-2, a concentration of IL-2 reported to support ex vivo Treg survival and expansion and intermediate to those reported in published studies. The expansion procedure can be adapted to conditions known to support optimal Treg expansion. Tconv will be grown in complete medium supplemented with 50 U / ml IL-2 and 1 ng / ml IL-15.
[0186] The suppressor function of TGF-β CAR-Tregs can be assessed in co-culture with target Tconvs. Target Tconvs are CD4+ T cells transduced with lentivirus to express CD19 CAR. To assess Treg function, TGF-β CAR-Tregs can be co-incubated with both CFSE-labeled CD19 CAR-Tconvs and CD19+ Raji lymphoma cells in the presence or absence of soluble TGF-β. Proliferation of CD19 CAR-Tconvs can be assessed by CFSE dilution as well as by viable cell counting by flow cytometry. To clearly distinguish Treg proliferation from Tconv proliferation in this co-culture situation, a CFSE-based proliferation assay can be performed instead of the more widely used 3H-thymidine incorporation assay. CFSE-labeled cells can be accurately quantified from early time points by flow cytometry, while the CFSE dilution peak will represent cell division kinetics over a 7-day period. As a negative control, TGF-β CAR-Tconv or scFv-less CAR-Treg can be substituted for TGF-β CAR-Treg in the co-incubation samples. While scFv-less CAR-Treg will show some suppressive function, TGF-β CAR-Treg is expected to have enhanced suppression due to the production of TGF-β and subsequent autocrine Treg activation via TGF-β CAR. Moreover, the addition of exogenous TGF-β is expected to further enhance the suppressor function of TGF-β CAR-Treg, thereby minimizing the expansion of CD19 CAR-Tconv despite the presence of CD19+ target cells.
[0187] Validation of the suppressor function of TGF-β CAR-Tregs in vitro allows estimation of the ability of engineered Tregs to perform suppressor function in vivo. For animal studies, mouse CD4+ / CD25+ Tregs will be isolated from lymph nodes and spleens of DBA / 1 mice by magnetic bead-based cell sorting. As previously described for human Tregs, sorted cells can be activated, transduced, expanded, and sorted with mouse CD3 / CD28 Dynabeads for expression of TGF-β CAR. Although the TGF-β CAR is constructed with an scFv targeting human TGF-β, we confirmed that this receptor cross-reacts with mouse TGF-β with high efficiency (Figure 8). To induce collagen-induced arthritis (CIA), DBA / 1 mice can be injected at the base of the tail with 100 μl of an emulsion containing 2 mg / ml chicken type II collagen in PBS mixed 1:1 with 0.1 M acetic acid, complete Freund's adjuvant. One day before CIA immunization or two weeks after CIA immunization, one million Tregs can be administered via tail vein injection to evaluate Treg performance at different stages of disease progression. TGF-β CAR-Tregs can be compared against no scFv CAR-Tregs and "no Treg" controls (i.e., controls where no Tregs are administered after CIA immunization) for their ability to prevent or ameliorate arthritis. Mice can be assessed for clinical arthritis in the paws based on a four-point scale as previously described by Kelchtermans, H. et al. (Arthritis Res Ther 7, R402-415 (2005)). Ten animals can be included in each test condition (total of 40 animals). A sample size of n=10 provides 92% power to detect a difference of 1.5 standard deviations in arthritis scored by a two-tailed t-test at α=0.05. Based on available literature, it is expected that scFv-less CAR-Tregs will achieve significant suppression of arthritis symptoms in the CIA model. Meanwhile, the addition of TGF-β CAR is expected to enhance Treg functionality, resulting in more effective inhibition of CIA.Whether a long-spacer CAR or a short-spacer CAR exhibits superior in vivo functionality in the CIA model remains to be determined.
[0188] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that changes may be made to the methods and in the steps or sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. All references, citations, patent publications, and sequences associated with any Genbank Accession Numbers listed in are specifically incorporated herein by reference in their entirety for all purposes.
[0189] References The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. TIFF2024155943000066.tif19128TIFF2024155943000067.tif241145TIFF2024155943000068.tif240147
[0190] Sequence information SEQUENCE LISTING <110> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA <120> TRANSFORMING GROWTH FACTOR-BETA-RESPONSIVE POLYPEPTIDES AND THEIR METHODS FOR USE <150> US 62 / 248,685 <151> 2015-10-30 <160> 101 <170> PatentIn version 3.5 <210> 1 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 1 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ala Phe Thr Asn Tyr 20 25 30 Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Val Ile Asn Pro Gly Ser Gly Gly Ser Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Arg Ala Thr Ile Ser Ala Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Gly Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 <210> 2 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 2 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys 35 40 45 Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys His Gln 85 90 95 Tyr Leu Ser Ser Asp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala 115 <210> 3 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 3 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Asn 20 25 30 Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Val Ile Pro Ile Val Asp Ile Ala Asn Tyr Ala Gln Arg Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Leu Pro Arg Ala Phe Val Leu Asp Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 4 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 4 Glu Thr Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Leu Gly Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Pro Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ala Asp Ser Pro 85 90 95 Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 5 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 5 Gly Tyr Ala Phe Thr Asn Tyr Leu Ile Glu 1 5 10 <210> 6 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 6 Val Ile Asn Pro Gly Ser Gly Gly Ser Asn Tyr Asn Glu Lys Phe Lys 1 5 10 15 Gly <210> 7 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 7 Ser Gly Gly Phe Tyr Phe Asp Tyr 1 5 <210> 8 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 8 Arg Ala Ser Gln Ser Val Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu 1 5 10 15 Ala <210> 9 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 9 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 10 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 10 His Gln Tyr Leu Ser Ser Asp Thr 1 5 <210> 11 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 11 Ser Asn Val Ile Ser 1 5 <210> 12 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 12 Gly Val Ile Pro Ile Val Asp Ile Ala Asn Tyr Ala Gln Arg Phe Lys 1 5 10 15 Gly <210> 13 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 13 Pro Arg Ala Phe Val Leu Asp Ala Met Asp Tyr 1 5 10 <210> 14 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 14 Arg Ala Ser Gln Ser Leu Gly Ser Ser Tyr Leu Ala 1 5 10 <210> 15 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 15 Gly Ala Ser Ser Arg Ala Pro 1 5 <210> 16 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 16 Gln Gln Tyr Ala Asp Ser Pro Ile Thr 1 5 <210> 17 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 17 Asp Tyr Lys Asp Asp Asp Asp Lys 1 5 <210> 18 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 18 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly 20 <210> 19 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 19 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Glu Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Asp Pro Gln Tyr Ser 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 20 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 20 Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Gly Ile Gly Asp Asp 20 25 30 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Ile Leu Leu Ile 35 40 45 Tyr Gly Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Ser Asn Tyr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 21 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 21 Ser Tyr Gly Met His 1 5 <210> 22 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 22 Val Ile Ser Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 23 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 23 Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Asp Pro Gln Tyr Ser 1 5 10 <210> 24 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 24 Arg Ser Ser Gln Gly Ile Gly Asp Asp Leu Gly 1 5 10 <210> 25 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 25 Gly Thr Ser Thr Leu Gln Ser 1 5 <210> 26 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 26 Leu Gln Asp Ser Asn Tyr Pro Leu Thr 1 5 <210> 27 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 27 Asp Lys Thr His Thr 1 5 <210> 28 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 28 Cys Pro Pro Cys 1 <210> 29 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 29 Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg 1 5 10 15 <210> 30 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 30 Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr 1 5 10 <210> 31 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 31 Lys Ser Cys Asp Lys Thr His Thr Cys Pro 1 5 10 <210> 32 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 32 Lys Cys Cys Val Asp Cys Pro 1 5 <210> 33 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 33 Lys Tyr Gly Pro Pro Cys Pro 1 5 <210> 34 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 34 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 1 5 10 15 <210> 35 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 35 Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 1 5 10 <210> 36 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 36 Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys 1 5 10 15 Pro <210> 37 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 37 Ser Pro Asn Met Val Pro His Ala His His Ala Gln 1 5 10 <210> 38 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 38 Glu Pro Lys Ser Cys Asp Lys Thr Tyr Thr Cys Pro Pro Cys Pro 1 5 10 15 <210> 39 <211> 45 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 39 Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala 1 5 10 15 Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly 20 25 30 Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp 35 40 45 <210> 40 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (1)..(4) <223> Repeated more than once <400> 40 Gly Ser Gly Gly Ser 1 5 <210> 41 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (1)..(4) <223> Repeated more than once <400> 41 Gly Gly Gly Ser 1 <210> 42 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 42 Gly Gly Ser Gly 1 <210> 43 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 43 Gly Gly Ser Gly Gly 1 5 <210> 44 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 44 Gly Ser Gly Ser Gly 1 5 <210> 45 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 45 Gly Ser Gly Gly Gly 1 5 <210> 46 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 46 Gly Gly Gly Ser Gly 1 5 <210> 47 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 47 Gly Ser Ser Ser Gly 1 5 <210> 48 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptides <400> 48 Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu 1 5 10 15 Serum Leu Val Ile Thr Leu Tyr Cys 20 <210> 49 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptides <400> 49 Leu Gly Leu Leu Val Ala Gly Val Leu Val Leu Leu Val Ser Leu Gly 1 5 10 15 Val Ala Ile His Leu Cys Cys 20 <210> 50 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptides <400> 50 Ala Leu Ile Val Leu Gly Gly Val Ala Gly Leu Leu Leu Phe Ile Gly 1 5 10 15 Leu Gly Ile Phe Phe Cys Val Arg Cys 20 25 <210> 51 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptides <400> 51 Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu 1 5 10 15 Thr Ala Leu Phe Leu Arg Val 20 <210> 52 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptides <400> 52 Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu 1 5 10 15 Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25 <210> 53 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptides <400> 53 Val Ala Ala Ile Leu Gly Leu Gly Leu Val Leu Gly Leu Leu Gly Pro 1 5 10 15 Leo Ala Ile Leo Leo Ala Leo Tyr Leo Leo 20 25 <210> 54 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 54 Ala Leu Pro Ala Ala Leu Ala Val Ile Ser Phe Leu Leu Gly Leu Gly 1 5 10 15 Leu Gly Val Ala Cys Val Leu Ala 20 <210> 55 <211> 42 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 55 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 1 5 10 15 Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 20 25 30 Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 35 40 <210> 56 <211> 44 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 56 Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met 1 5 10 15 Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro 20 25 30 Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 40 <210> 57 <211> 35 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 57 Thr Lys Lys Lys Tyr Ser Ser Ser Val His Asp Pro Asn Gly Glu Tyr 1 5 10 15 Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser Arg Leu Thr Asp 20 25 30 Val Thr Leu 35 <210> 58 <211> 37 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 58 Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly 1 5 10 15 Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser 20 25 30 Thr Leu Ala Lys Ile 35 <210> 59 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 59 Cys Cys Leu Arg Arg His Gln Gly Lys Gln Asn Glu Leu Ser Asp Thr 1 5 10 15 Ala Gly Arg Glu Ile Asn Leu Val Asp Ala His Leu Lys Ser Glu Gln 20 25 30 Thr Glu Ala Ser Thr Arg Gln Asn Ser Gln Val Leu Leu Ser Glu Thr 35 40 45 Gly Ile Tyr Asp Asn Asp Pro Asp Leu Cys Phe Arg Met Gln Glu Gly 50 55 60 Ser Glu Val Tyr Ser Asn Pro Cys Leu Glu Glu Asn Lys Pro Gly Ile 65 70 75 80 Val Tyr Ala Ser Leu Asn His Ser Val Ile Gly Pro Asn Ser Arg Leu 85 90 95 Ala Arg Asn Val Lys Glu Ala Pro Thr Glu Tyr Ala Ser Ile Cys Val 100 105 110 Arg Ser <210> 60 <211> 49 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 60 His Gln Arg Arg Lys Tyr Arg Ser Asn Lys Gly Glu Ser Pro Val Glu 1 5 10 15 Pro Ala Glu Pro Cys Arg Tyr Ser Cys Pro Arg Glu Glu Glu Gly Ser 20 25 30 Thr Ile Pro Ile Gln Glu Asp Tyr Arg Lys Pro Glu Pro Ala Cys Ser 35 40 45 Pro <210> 61 <211> 187 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 61 Arg Arg Ala Cys Arg Lys Arg Ile Arg Gln Lys Leu His Leu Cys Tyr 1 5 10 15 Pro Val Gln Thr Ser Gln Pro Lys Leu Glu Leu Val Asp Ser Arg Pro 20 25 30 Arg Arg Ser Ser Thr Gln Leu Arg Ser Gly Ala Ser Val Thr Glu Pro 35 40 45 Val Ala Glu Glu Arg Gly Leu Met Ser Gln Pro Leu Met Glu Thr Cys 50 55 60 His Ser Val Gly Ala Ala Tyr Leu Glu Ser Leu Pro Leu Gln Asp Ala 65 70 75 80 Ser Pro Ala Gly Gly Pro Ser Ser Pro Arg Asp Leu Pro Glu Pro Arg 85 90 95 Val Ser Thr Glu His Thr Asn Asn Lys Ile Glu Lys Ile Tyr Ile Met 100 105 110 Lys Ala Asp Thr Val Ile Val Gly Thr Val Lys Ala Glu Leu Pro Glu 115 120 125 Gly Arg Gly Leu Ala Gly Pro Ala Glu Pro Glu Leu Glu Glu Glu Leu 130 135 140 Glu Ala Asp His Thr Pro His Tyr Pro Glu Gln Glu Thr Glu Pro Pro 145 150 155 160 Leu Gly Ser Cys Ser Asp Val Met Leu Ser Val Glu Glu Glu Gly Lys 165 170 175 Glu Asp Pro Leu Pro Thr Ala Ala Ser Gly Lys 180 185 <210> 62 <211> 54 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 62 His Ile Trp Gln Leu Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln 1 5 10 15 Leu Leu Leu Glu Val Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln 20 25 30 Phe Pro Glu Glu Glu Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg 35 40 45 Leu Gly Asp Leu Trp Val 50 <210> 63 <211> 60 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 63 Cys Val Lys Arg Arg Lys Pro Arg Gly Asp Val Val Lys Val Ile Val 1 5 10 15 Ser Val Gln Arg Lys Arg Gln Glu Ala Glu Gly Glu Ala Thr Val Ile 20 25 30 Glu Ala Leu Gln Ala Pro Pro Asp Val Thr Thr Val Ala Val Glu Glu 35 40 45 Thr Ile Pro Ser Phe Thr Gly Arg Ser Pro Asn His 50 55 60 <210> 64 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (2)..(3) <223> X is any amino acid <220> <221> MISC_FEATURE <222> (4)..(4) <223> X is leucine or isoleucine <400> 64 Tyr Xaa Xaa Xaa 1 <210> 65 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (2)..(3) <223> X is any amino acid <220> <221> MISC_FEATURE <222> (4)..(4) <223> X is leucine or isoleucine <220> <221> MISC_FEATURE <222> (5)..(12) <223> X is any amino acid or absent <220> <221> MISC_FEATURE <222> (14)..(15) <223> X is any amino acid <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is leucine or isoleucine <400> 65 Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa 1 5 10 15 <210> 66 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (82)..(82) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (92)..(92) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (95)..(95) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (97)..(97) <223> X is pyrrolysine <400> 66 Met Gly Gly Leu Glu Pro Cys Ser Arg Leu Leu Leu Leu Pro Leu Leu 1 5 10 15 Leu Ala Val Ser Gly Leu Arg Pro Val Gln Ala Gln Ala Gln Ser Asp 20 25 30 Cys Ser Cys Ser Thr Val Ser Pro Gly Val Leu Ala Gly Ile Val Met 35 40 45 Gly Asp Leu Val Leu Thr Val Leu Ile Ala Leu Ala Val Tyr Phe Leu 50 55 60 Gly Arg Leu Val Pro Arg Gly Arg Gly Ala Ala Glu Ala Ala Thr Arg 65 70 75 80 Lys Xaa Arg Ile Thr Glu Thr Glu Ser Pro Tyr Xaa Glu Leu Xaa Gly 85 90 95 Xaa Arg Ser Asp Val Tyr Ser Asp Leu Asn Thr Gln Arg Pro Tyr Tyr 100 105 110 Lys <210> 67 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (81)..(81) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (91)..(91) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (94)..(94) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (96)..(96) <223> X is pyrrolysine <400> 67 Met Gly Gly Leu Glu Pro Cys Ser Arg Leu Leu Leu Leu Pro Leu Leu 1 5 10 15 Leu Ala Val Ser Gly Leu Arg Pro Val Gln Ala Gln Ala Gln Ser Asp 20 25 30 Cys Ser Cys Ser Thr Val Ser Pro Gly Val Leu Ala Gly Ile Val Met 35 40 45 Gly Asp Leu Val Leu Thr Val Leu Ile Ala Leu Ala Val Tyr Phe Leu 50 55 60 Gly Arg Leu Val Pro Arg Gly Arg Gly Ala Ala Glu Ala Thr Arg Lys 65 70 75 80 Xaa Arg Ile Thr Glu Thr Glu Ser Pro Tyr Xaa Glu Leu Xaa Gly Xaa 85 90 95 Arg Ser Asp Val Tyr Ser Asp Leu Asn Thr Gln Arg Pro Tyr Tyr Lys 100 105 110 <210> 68 <211> 102 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (71)..(71) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (81)..(81) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (84)..(84) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (86)..(86) <223> X is pyrrolysine <400> 68 Met Gly Gly Leu Glu Pro Cys Ser Arg Leu Leu Leu Leu Pro Leu Leu 1 5 10 15 Leu Ala Val Ser Asp Cys Ser Cys Ser Thr Val Ser Pro Gly Val Leu 20 25 30 Ala Gly Ile Val Met Gly Asp Leu Val Leu Thr Val Leu Ile Ala Leu 35 40 45 Ala Val Tyr Phe Leu Gly Arg Leu Val Pro Arg Gly Arg Gly Ala Ala 50 55 60 Glu Ala Ala Thr Arg Lys Xaa Arg Ile Thr Glu Thr Glu Ser Pro Tyr 65 70 75 80 Xaa Glu Leu Xaa Gly Xaa Arg Ser Asp Val Tyr Ser Asp Leu Asn Thr 85 90 95 Gln Arg Pro Tyr Tyr Lys 100 <210> 69 <211> 101 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (70)..(70) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (80)..(80) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (83)..(83) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (85)..(85) <223> X is pyrrolysine <400> 69 Met Gly Gly Leu Glu Pro Cys Ser Arg Leu Leu Leu Leu Pro Leu Leu 1 5 10 15 Leu Ala Val Ser Asp Cys Ser Cys Ser Thr Val Ser Pro Gly Val Leu 20 25 30 Ala Gly Ile Val Met Gly Asp Leu Val Leu Thr Val Leu Ile Ala Leu 35 40 45 Ala Val Tyr Phe Leu Gly Arg Leu Val Pro Arg Gly Arg Gly Ala Ala 50 55 60 Glu Ala Thr Arg Lys Xaa Arg Ile Thr Glu Thr Glu Ser Pro Tyr Xaa 65 70 75 80 Glu Leu Xaa Gly Xaa Arg Ser Asp Val Tyr Ser Asp Leu Asn Thr Gln 85 90 95 Arg Pro Tyr Tyr Lys 100 <210> 70 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (10)..(10) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (21)..(21) <223> X is pyrrolysine <400> 70 Glu Ser Pro Tyr Xaa Glu Leu Xaa Gly Xaa Arg Ser Asp Val Tyr Ser 1 5 10 15 Asp Leu Asn Thr Xaa 20 <210> 71 <211> 86 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 71 Met Ile Pro Ala Val Val Leu Leu Leu Leu Leu Leu Val Glu Gln Ala 1 5 10 15 Ala Ala Leu Gly Glu Pro Gln Leu Cys Tyr Ile Leu Asp Ala Ile Leu 20 25 30 Phe Leu Tyr Gly Ile Val Leu Thr Leu Leu Tyr Cys Arg Leu Lys Ile 35 40 45 Gln Val Arg Lys Ala Ala Ile Thr Ser Tyr Glu Lys Ser Asp Gly Val 50 55 60 Tyr Thr Gly Leu Ser Thr Arg Asn Gln Glu Thr Tyr Glu Thr Leu Lys 65 70 75 80 His Glu Lys Pro Pro Gln 85 <210> 72 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (12)..(12) <223> X is pyrrolysine <400> 72 Asp Gly Val Tyr Thr Gly Leu Ser Thr Arg Asn Xaa Glu Thr Tyr Glu 1 5 10 15 Thr Leu Lys His Glu 20 <210> 73 <211> 171 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (140)..(140) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (147)..(147) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (150)..(150) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (159)..(159) <223> X is pyrrolysine <400> 73 Met Glu His Ser Thr Phe Leu Ser Gly Leu Val Leu Ala Thr Leu Leu 1 5 10 15 Ser Gln Val Ser Pro Phe Lys Ile Pro Ile Glu Glu Leu Glu Asp Arg 20 25 30 Val Phe Val Asn Cys Asn Thr Ser Ile Thr Trp Val Glu Gly Thr Val 35 40 45 Gly Thr Leu Leu Ser Asp Ile Thr Arg Leu Asp Leu Gly Lys Arg Ile 50 55 60 Leu Asp Pro Arg Gly Ile Tyr Arg Cys Asn Gly Thr Asp Ile Tyr Lys 65 70 75 80 Asp Lys Glu Ser Thr Val Gln Val His Tyr Arg Met Cys Gln Ser Cys 85 90 95 Val Glu Leu Asp Pro Ala Thr Val Ala Gly Ile Ile Val Thr Asp Val 100 105 110 Ile Ala Thr Leu Leu Leu Ala Leu Gly Val Phe Cys Phe Ala Gly His 115 120 125 Glu Thr Gly Arg Leu Ser Gly Ala Ala Asp Thr Xaa Ala Leu Leu Arg 130 135 140 Asn Asp Xaa Val Tyr Xaa Pro Leu Arg Asp Arg Asp Asp Ala Xaa Tyr 145 150 155 160 Ser His Leu Gly Gly Asn Trp Ala Arg Asn Lys 165 170 <210> 74 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (87)..(87) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (96)..(96) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (103)..(103) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (106)..(106) <223> X is pyrrolysine <400> 74 Met Glu His Ser Thr Phe Leu Ser Gly Leu Val Leu Ala Thr Leu Leu 1 5 10 15 Ser Gln Val Ser Pro Phe Lys Ile Pro Ile Glu Glu Leu Glu Asp Arg 20 25 30 Val Phe Val Asn Cys Asn Thr Ser Ile Thr Trp Val Glu Gly Thr Val 35 40 45 Gly Thr Leu Leu Ser Asp Ile Thr Arg Leu Asp Leu Gly Lys Arg Ile 50 55 60 Leu Asp Pro Arg Gly Ile Tyr Arg Cys Asn Gly Thr Asp Ile Tyr Lys 65 70 75 80 Asp Lys Glu Ser Thr Val Xaa Val His Tyr Arg Thr Ala Asp Thr Xaa 85 90 95 Ala Leu Leu Arg Asn Asp Xaa Val Tyr Xaa Pro Leu Arg Asp Arg Asp 100 105 110 Asp Ala Gln Tyr Ser His Leu Gly Gly Asn Trp Ala Arg Asn Lys 115 120 125 <210> 75 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is pyrrolysine <400> 75 Asp Xaa Val Tyr Xaa Pro Leu Arg Asp Arg Asp Asp Ala Xaa Tyr Ser 1 5 10 15 His Leu Gly Gly Asn 20 <210> 76 <211> 207 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 76 Met Gln Ser Gly Thr His Trp Arg Val Leu Gly Leu Cys Leu Leu Ser 1 5 10 15 Val Gly Val Trp Gly Gln Asp Gly Asn Glu Glu Met Gly Gly Ile Thr 20 25 30 Gln Thr Pro Tyr Lys Val Ser Ile Ser Gly Thr Thr Val Ile Leu Thr 35 40 45 Cys Pro Gln Tyr Pro Gly Ser Glu Ile Leu Trp Gln His Asn Asp Lys 50 55 60 Asn Ile Gly Gly Asp Glu Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp 65 70 75 80 His Leu Ser Leu Lys Glu Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr 85 90 95 Val Cys Tyr Pro Arg Gly Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu 100 105 110 Tyr Leu Arg Ala Arg Val Cys Glu Asn Cys Met Glu Met Asp Val Met 115 120 125 Ser Val Ala Thr Ile Val Ile Val Asp Ile Cys Ile Thr Gly Gly Leu 130 135 140 Leu Leu Leu Val Tyr Tyr Trp Ser Lys Asn Arg Lys Ala Lys Ala Lys 145 150 155 160 Pro Val Thr Arg Gly Ala Gly Ala Gly Gly Arg Gln Arg Gly Gln Asn 165 170 175 Lys Glu Arg Pro Pro Pro Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg 180 185 190 Lys Gly Gln Arg Asp Leu Tyr Ser Gly Leu Asn Gln Arg Arg Ile 195 200 205 <210> 77 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 77 Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Arg Asp Leu Tyr Ser 1 5 10 15 Gly Leu Asn Gln Arg 20 <210> 78 <211> 182 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (139)..(139) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (144)..(144) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (151)..(151) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (158)..(158) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (161)..(161) <223> X is pyrrolysine <400> 78 Met Glu Gln Gly Lys Gly Leu Ala Val Leu Ile Leu Ala Ile Ile Leu 1 5 10 15 Leu Gln Gly Thr Leu Ala Gln Ser Ile Lys Gly Asn His Leu Val Lys 20 25 30 Val Tyr Asp Tyr Gln Glu Asp Gly Ser Val Leu Leu Thr Cys Asp Ala 35 40 45 Glu Ala Lys Asn Ile Thr Trp Phe Lys Asp Gly Lys Met Ile Gly Phe 50 55 60 Leu Thr Glu Asp Lys Lys Lys Trp Asn Leu Gly Ser Asn Ala Lys Asp 65 70 75 80 Pro Arg Gly Met Tyr Gln Cys Lys Gly Ser Gln Asn Lys Ser Lys Pro 85 90 95 Leu Gln Val Tyr Tyr Arg Met Cys Gln Asn Cys Ile Glu Leu Asn Ala 100 105 110 Ala Thr Ile Ser Gly Phe Leu Phe Ala Glu Ile Val Ser Ile Phe Val 115 120 125 Leu Ala Val Gly Val Tyr Phe Ile Ala Gly Xaa Asp Gly Val Arg Xaa 130 135 140 Ser Arg Ala Ser Asp Lys Xaa Thr Leu Leu Pro Asn Asp Xaa Leu Tyr 145 150 155 160 Xaa Pro Leu Lys Asp Arg Glu Asp Asp Gln Tyr Ser His Leu Gln Gly 165 170 175 Asn Gln Leu Arg Arg Asn 180 <210> 79 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is pyrrolysine <400> 79 Asp No Tyr No Pro Leu Lys Asp Arg Glu Asp Asp No Tyr Ser 1 5 10 15 His Leu Gly Asn 20 <210> 80 <211> 163 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURES <222> (114)..(114) <223> X is pyrrolysine. <220> <221> MISC_FEATURES <222> (142)..(142) <223> X is pyrrolysine. <400> 80 Met Lys Trp Lys Falcon Phe Thr Falcon Ile Leu Gln Falcon Gln Leu 1 5 10 15 Pro Ile Thr Glu Ala Gln Ser Phe Gly Leu Leu Asp Pro Lys Leu Cys 20 25 30 Tyr Leu Leu Asp Gly Leu Phe Leu Leu Phe Leu Tyr Gly Val Leu Leu Thr Ala 35 40 45 Leu Phe Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr 50 55 60 Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg 65 70 75 80 Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met 85 90 95 Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu 100 105 110 Leu Xaa Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys 115 120 125 Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Xaa Gly Leu 130 135 140 Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu 145 150 155 160 Pro Pro Arg <210> 81 <211> 164 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (115)..(115) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (143)..(143) <223> X is pyrrolysine <400> 81 Met Lys Trp Lys Ala Leu Phe Thr Ala Ala Ile Leu Gln Ala Gln Leu 1 5 10 15 Pro Ile Thr Glu Ala Gln Ser Phe Gly Leu Leu Asp Pro Lys Leu Cys 20 25 30 Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala 35 40 45 Leu Phe Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr 50 55 60 Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg 65 70 75 80 Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met 85 90 95 Gly Gly Lys Pro Gln Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn 100 105 110 Glu Leu Xaa Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met 115 120 125 Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Xaa Gly 130 135 140 Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala 145 150 155 160 Leu Pro Pro Arg <210> 82 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (17)..(17) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (55)..(55) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (63)..(63) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (91)..(91) <223> X is pyrrolysine <400> 82 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Xaa Gln Gly 1 5 10 15 Xaa Asn Xaa Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Xaa Glu Gly Leu Tyr Asn Glu Leu Xaa Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Xaa Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 83 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is pyrrolysine <400> 83 Asn Xaa Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp 1 5 10 15 Val Leu Asp Lys Arg 20 <210> 84 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 84 Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr 1 5 10 15 Ser Glu Ile Gly Met Lys 20 <210> 85 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (21)..(21) <223> X is pyrrolysine <400> 85 Asp Gly Leu Tyr Xaa Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp 1 5 10 15 Ala Leu His Met Xaa 20 <210> 86 <211> 226 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <220> <221> MISC_FEATURE <222> (170)..(170) <223> X is pyrrolysine <220> <221> MISC_FEATURE <222> (207)..(207) <223> X is pyrrolysine <400> 86 Met Pro Gly Gly Pro Gly Val Leu Gln Ala Leu Pro Ala Thr Ile Phe 1 5 10 15 Leu Leu Phe Leu Leu Ser Ala Val Tyr Leu Gly Pro Gly Cys Gln Ala 20 25 30 Leu Trp Met His Lys Val Pro Ala Ser Leu Met Val Ser Leu Gly Glu 35 40 45 Asp Ala His Phe Gln Cys Pro His Asn Ser Ser Asn Asn Ala Asn Val 50 55 60 Thr Trp Trp Arg Val Leu His Gly Asn Tyr Thr Trp Pro Pro Glu Phe 65 70 75 80 Leu Gly Pro Gly Glu Asp Pro Asn Gly Thr Leu Ile Ile Gln Asn Val 85 90 95 Asn Lys Ser His Gly Gly Ile Tyr Val Cys Arg Val Gln Glu Gly Asn 100 105 110 Glu Ser Tyr Gln Gln Ser Cys Gly Thr Tyr Leu Arg Val Arg Gln Pro 115 120 125 Pro Pro Arg Pro Phe Leu Asp Met Gly Glu Gly Thr Lys Asn Arg Ile 130 135 140 Ile Thr Ala Glu Gly Ile Ile Leu Leu Phe Cys Ala Val Val Pro Gly 145 150 155 160 Thr Leu Leu Leu Phe Arg Lys Arg Trp Xaa Asn Glu Lys Leu Gly Leu 165 170 175 Asp Ala Gly Asp Glu Tyr Glu Asp Glu Asn Leu Tyr Glu Gly Leu Asn 180 185 190 Leu Asp Asp Cys Ser Met Tyr Glu Asp Ile Ser Arg Gly Leu Xaa Gly 195 200 205 Thr Tyr Gln Asp Val Gly Ser Leu Asn Ile Gly Asp Val Gln Leu Glu 210 215 220 Lys Pro 225 <210> 87 <211> 188 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 87 Met Pro Gly Gly Pro Gly Val Leu Gln Ala Leu Pro Ala Thr Ile Phe 1 5 10 15 Leu Leu Phe Leu Leu Ser Ala Val Tyr Leu Gly Pro Gly Cys Gln Ala 20 25 30 Leu Trp Met His Lys Val Pro Ala Ser Leu Met Val Ser Leu Gly Glu 35 40 45 Asp Ala His Phe Gln Cys Pro His Asn Ser Ser Asn Asn Ala Asn Val 50 55 60 Thr Trp Trp Arg Val Leu His Gly Asn Tyr Thr Trp Pro Pro Glu Phe 65 70 75 80 Leu Gly Pro Gly Glu Asp Pro Asn Glu Pro Pro Pro Arg Pro Phe Leu 85 90 95 Asp Met Gly Glu Gly Thr Lys Asn Arg Ile Ile Thr Ala Glu Gly Ile 100 105 110 Ile Leu Leu Phe Cys Ala Val Val Pro Gly Thr Leu Leu Leu Phe Arg 115 120 125 Lys Arg Trp Gln Asn Glu Lys Leu Gly Leu Asp Ala Gly Asp Glu Tyr 130 135 140 Glu Asp Glu Asn Leu Tyr Glu Gly Leu Asn Leu Asp Asp Cys Ser Met 145 150 155 160 Tyr Glu Asp Ile Ser Arg Gly Leu Gln Gly Thr Tyr Gln Asp Val Gly 165 170 175 Ser Leu Asn Ile Gly Asp Val Gln Leu Glu Lys Pro 180 185 <210> 88 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 88 Glu Asn Leu Tyr Glu Gly Leu Asn Leu Asp Asp Cys Ser Met Tyr Glu 1 5 10 15 Asp Ile Ser Arg Gly 20 <210> 89 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 89 Arg Pro Arg Arg Ser Pro Ala Gln Asp Gly Lys Val Tyr Ile Asn Met 1 5 10 15 Pro Gly Arg Gly 20 <210> 90 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 90 Arg Pro Arg Arg Ser Pro Ala Gln Asp Gly Lys Val Tyr Ile Asn Met 1 5 10 15 Pro Gly Arg Gly 20 <210> 91 <211> 68 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 91 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser 20 25 30 Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly 35 40 45 Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala 50 55 60 Alas Tyr Arg Dear 65 <210> 92 <211> 68 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 92 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser 20 25 30 Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly 35 40 45 Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala 50 55 60 Alas Tyr Arg Dear 65 <210> 93 <211> 619 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 93 Met Pro Asp Pro Ala Ala His Leu Pro Phe Phe Tyr Gly Ser Ile Ser 1 5 10 15 Arg Ala Glu Ala Glu Glu His Leu Lys Leu Ala Gly Met Ala Asp Gly 20 25 30 Leu Phe Leu Leu Arg Gln Cys Leu Arg Ser Leu Gly Gly Tyr Val Leu 35 40 45 Ser Leu Val His Asp Val Arg Phe His His Phe Pro Ile Glu Arg Gln 50 55 60 Leu Asn Gly Thr Tyr Ala Ile Ala Gly Gly Lys Ala His Cys Gly Pro 65 70 75 80 Ala Glu Leu Cys Glu Phe Tyr Ser Arg Asp Pro Asp Gly Leu Pro Cys 85 90 95 Asn Leu Arg Lys Pro Cys Asn Arg Pro Ser Gly Leu Glu Pro Gln Pro 100 105 110 Gly Val Phe Asp Cys Leu Arg Asp Ala Met Val Arg Asp Tyr Val Arg 115 120 125 Gln Thr Trp Lys Leu Glu Gly Glu Ala Leu Glu Gln Ala Ile Ile Ser 130 135 140 Gln Ala Pro Gln Val Glu Lys Leu Ile Ala Thr Thr Ala His Glu Arg 145 150 155 160 Met Pro Trp Tyr His Ser Ser Leu Thr Arg Glu Glu Ala Glu Arg Lys 165 170 175 Leu Tyr Ser Gly Ala Gln Thr Asp Gly Lys Phe Leu Leu Arg Pro Arg 180 185 190 Lys Glu Gln Gly Thr Tyr Ala Leu Ser Leu Ile Tyr Gly Lys Thr Val 195 200 205 Tyr His Tyr Leu Ile Ser Gln Asp Lys Ala Gly Lys Tyr Cys Ile Pro 210 215 220 Glu Gly Thr Lys Phe Asp Thr Leu Trp Gln Leu Val Glu Tyr Leu Lys 225 230 235 240 Leu Lys Ala Asp Gly Leu Ile Tyr Cys Leu Lys Glu Ala Cys Pro Asn 245 250 255 Ser Ser Ala Ser Asn Ala Ser Gly Ala Ala Ala Pro Thr Leu Pro Ala 260 265 270 His Pro Ser Thr Leu Thr His Pro Gln Arg Arg Ile Asp Thr Leu Asn 275 280 285 Ser Asp Gly Tyr Thr Pro Glu Pro Ala Arg Ile Thr Ser Pro Asp Lys 290 295 300 Pro Arg Pro Met Pro Met Asp Thr Ser Val Tyr Glu Ser Pro Tyr Ser 305 310 315 320 Asp Pro Glu Glu Leu Lys Asp Lys Lys Leu Phe Leu Lys Arg Asp Asn 325 330 335 Leu Leu Ile Ala Asp Ile Glu Leu Gly Cys Gly Asn Phe Gly Ser Val 340 345 350 Arg Gln Gly Val Tyr Arg Met Arg Lys Lys Gln Ile Asp Val Ala Ile 355 360 365 Lys Val Leu Lys Gln Gly Thr Glu Lys Ala Asp Thr Glu Glu Met Met 370 375 380 Arg Glu Ala Gln Ile Met His Gln Leu Asp Asn Pro Tyr Ile Val Arg 385 390 395 400 Leu Ile Gly Val Cys Gln Ala Glu Ala Leu Met Leu Val Met Glu Met 405 410 415 Ala Gly Gly Gly Pro Leu His Lys Phe Leu Val Gly Lys Arg Glu Glu 420 425 430 Ile Pro Val Ser Asn Val Ala Glu Leu Leu His Gln Val Ser Met Gly 435 440 445 Met Lys Tyr Leu Glu Glu Lys Asn Phe Val His Arg Asp Leu Ala Ala 450 455 460 Arg Asn Val Leu Leu Val Asn Arg His Tyr Ala Lys Ile Ser Asp Phe 465 470 475 480 Gly Leu Ser Lys Ala Leu Gly Ala Asp Asp Ser Tyr Tyr Thr Ala Arg 485 490 495 Ser Ala Gly Lys Trp Pro Leu Lys Trp Tyr Ala Pro Glu Cys Ile Asn 500 505 510 Phe Arg Lys Phe Ser Ser Arg Ser Asp Val Trp Ser Tyr Gly Val Thr 515 520 525 Met Trp Glu Ala Leu Ser Tyr Gly Gln Lys Pro Tyr Lys Lys Met Lys 530 535 540 Gly Pro Glu Val Met Ala Phe Ile Glu Gln Gly Lys Arg Met Glu Cys 545 550 555 560 Pro Pro Glu Cys Pro Pro Glu Leu Tyr Ala Leu Met Ser Asp Cys Trp 565 570 575 Ile Tyr Lys Trp Glu Asp Arg Pro Asp Phe Leu Thr Val Glu Gln Arg 580 585 590 Met Arg Ala Cys Tyr Tyr Ser Leu Ala Ser Lys Val Glu Gly Pro Pro 595 600 605 Gly Ser Thr Gln Lys Ala Glu Ala Ala Cys Ala 610 615 <210> 94 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 94 Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 1 5 <210> 95 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 95 Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 1 5 10 <210> 96 <211> 290 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 96 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Ala Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys 20 25 30 Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 35 40 45 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ala Phe 50 55 60 Thr Asn Tyr Leu Ile Glu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 65 70 75 80 Glu Trp Val Gly Val Ile Asn Pro Gly Ser Gly Gly Ser Asn Tyr Asn 85 90 95 Glu Lys Phe Lys Gly Arg Ala Thr Ile Ser Ala Asp Asn Ser Lys Asn 100 105 110 Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 115 120 125 Tyr Tyr Cys Ala Arg Ser Gly Gly Phe Tyr Phe Asp Tyr Trp Gly Gln 130 135 140 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Gly 145 150 155 160 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile 165 170 175 Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg 180 185 190 Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Leu Tyr Ser Ser Asn 195 200 205 Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 210 215 220 Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Ser 225 230 235 240 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 245 250 255 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys His Gln Tyr Leu 260 265 270 Ser Ser Asp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 275 280 285 Val Ala 290 <210> 97 <211> 278 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 97 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Ala Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys 20 25 30 Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 35 40 45 Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 50 55 60 Ser Ser Asn Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 65 70 75 80 Glu Trp Met Gly Gly Val Ile Pro Ile Val Asp Ile Ala Asn Tyr Ala 85 90 95 Gln Arg Phe Lys Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser 100 105 110 Thr Thr Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 115 120 125 Tyr Tyr Cys Ala Leu Pro Arg Ala Phe Val Leu Asp Ala Met Asp Tyr 130 135 140 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser 145 150 155 160 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Thr Val Leu Thr Gln 165 170 175 Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser 180 185 190 Cys Arg Ala Ser Gln Ser Leu Gly Ser Ser Tyr Leu Ala Trp Tyr Gln 195 200 205 Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser 210 215 220 Arg Ala Pro Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr 225 230 235 240 Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val 245 250 255 Tyr Tyr Cys Gln Gln Tyr Ala Asp Ser Pro Ile Thr Phe Gly Gln Gly 260 265 270 Thr Arg Leu Glu Ile Lys 275 <210> 98 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 98 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro 1 5 10 <210> 99 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 99 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro 1 5 10 <210> 100 <211> 246 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 100 Asp Ile Val Leu Thr Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Asn Tyr Met 20 25 30 Asp Trp Tyr Gln Lys Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr 35 40 45 Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Phe Asn Pro Pro Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly Ser Thr Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Glu Val Gln Leu 115 120 125 Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met 130 135 140 Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met His Val 145 150 155 160 Trp Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr 165 170 175 Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala 180 185 190 Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser 195 200 205 Ser Leu Thr Ser Glu Asp Ser Ala Asp Tyr Tyr Cys Ala Arg Ser Asn 210 215 220 Tyr Tyr Gly Ser Ser Tyr Trp Phe Phe Asp Val Trp Gly Ala Gly Thr 225 230 235 240 Thr Val Thr Val Ser Ser 245 <210> 101 <211> 245 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 101 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Ser Thr Ser Gly 100 105 110 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys 115 120 125 Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser 130 135 140 Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser 145 150 155 160 Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile 165 170 175 Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu 180 185 190 Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn 195 200 205 Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr 210 215 220 Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 225 230 235 240 Val Thr Val Ser Ser 245
Claims
1. A polypeptide comprising a signal peptide, a TGF-β antigen-binding domain having a heavy chain variable (VH) region and a light chain variable (VL) region, a peptide spacer, a transmembrane domain, and an endodomain, and further comprising a costimulatory region between the transmembrane domain and the endodomain, the VH region comprises SEQ ID NO: 11 (HCDR1), SEQ ID NO: 12 (HCDR2), and SEQ ID NO: 13 (HCDR3), and the VL region comprises SEQ ID NO: 14 (LCDR1), SEQ ID NO: 15 (LCDR2), and SEQ ID NO: 16 (LCDR3); the peptide spacer comprises a hinge region of an IgG molecule; the transmembrane domain comprises the transmembrane domain of CD28; the endodomain comprises a CD3 zeta signaling domain and transmits an activation signal to the T cell after antigen binding; The polypeptide.
2. A polypeptide comprising a chimeric antigen receptor (CAR) comprising a signal peptide, a TGF-β antigen-binding domain which is a single-chain variable fragment having a heavy chain variable (VH) region and a light chain variable (VL) region, a peptide spacer comprising less than 50 amino acids, a transmembrane domain, and an endodomain.
3. The polypeptide of claim 1, wherein the TGF-β antigen binding domain comprises an scFv.
4. A polypeptide described in claim 1 or 2, wherein the VH region comprises SEQ ID NO:3 and the VL region comprises SEQ ID NO:
4.
5. The polypeptide according to claim 1, wherein the peptide spacer comprises the hinge region and CH 2 CH 3 region of an IgG molecule.
6. A polypeptide described in any one of claims 1 to 5, wherein the peptide spacer consists of a hinge region of an IgG molecule.
7. The polypeptide of claim 1, wherein the signal peptide comprises SEQ ID NO:
18.
8. A polypeptide described in any one of claims 1 to 7, comprising a CAR, the CAR being a bispecific CAR further comprising a cancer molecule-specific antigen-binding domain.
9. The polypeptide described in claim 8, wherein the cancer molecule-specific antigen-binding domain is specific to GD2 or IL-13R-a2.
10. The polypeptide of claim 8, wherein the cancer molecule-specific antigen-binding domain is specific to CAIX, CD33, CD44v7 / 8, CEA, EGP-2, EGP-40, erb-B2, erb-B3, erb-B4, FBP, fetal acetylcholine receptor, GD3, Her2 / neu, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, MUC1, NKG2D ligand, carcinoembryonic antigen h5T4, PSCA, PSMA, TAG-72, or VEGF-R2.
11. A polypeptide described in any one of claims 1 to 10, wherein the costimulatory region comprises a costimulatory region derived from 4-1BB or CD28.
12. An isolated nucleic acid encoding a polypeptide described in any one of claims 1 to 11.
13. A cell comprising a polypeptide described in any one of claims 1 to 11 or a nucleic acid described in claim 12.
14. The cell of claim 13, further comprising a cancer-specific chimeric antigen receptor (CAR).
15. The cell of claim 14, wherein the cancer-specific CAR specifically binds to GD2, IL-13R-a2, CAIX, CD33, CD44v7 / 8, CEA, EGP-2, EGP-40, erb-B2, erb-B3, erb-B4, FBP, fetal acetylcholine receptor, GD3, Her2 / neu, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, MUC1, NKG2D ligand, carcinoembryonic antigen h5T4, PSCA, PSMA, TAG-72, or VEGF-R2.
16. The cell of claim 15, which is an immune cell that is a CD4+ T cell, a CD8+ T cell, a regulatory T cell, a gamma delta T cell, or a cytotoxic T cell.
17. A pharmaceutical composition for use in a method for stimulating an immune response comprising a cell described in any one of claims 13 to 16, wherein the immune response is stimulated by contacting the cell with TGF-β.
18. The pharmaceutical composition of claim 17, wherein the cells are in vivo in a subject in need of immune stimulation.
19. A pharmaceutical composition for use in a method for treating cancer in a subject, comprising a cell according to any one of claims 13 to 16, said method comprising administering said cell to said subject having cancer.
20. The pharmaceutical composition of claim 18, wherein the subject has melanoma, brain tumor, B-cell malignancy, or breast cancer.
21. The pharmaceutical composition of claim 19, wherein the cancer comprises melanoma, brain tumor, B-cell malignancy, or breast cancer.
22. The pharmaceutical composition described in any one of claims 18 to 21, wherein the subject is a human subject.
